Document:

Amended and Restated Exclusive License Agreement

 [***] Information has been omitted and filed separately with the Securities and Exchange Commission.
Confidential Treatment has been requested with respect to the omitted portions. 
  
 Exhibit 10.4 
 Execution Version 

THE GENERAL HOSPITAL CORPORATION 

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT 
 MGH Amended and Restated Agreement No:              
 MGH Case No.: 1814 
 This Amended and Restated License Agreement
(“AGREEMENT”), is made as of September 21, 2011, between Zeltiq Aesthetics, Inc. a Delaware corporation, having a principal place of business at 4698 Willow Road, Pleasanton, CA 94588 (“COMPANY”), formerly known as Juniper
Medical, Inc., a Delaware corporation (“JUNIPER”), and The General Hospital Corporation, a not-for-profit corporation d/b/a Massachusetts General Hospital, having a place of business at 55 Fruit Street, Boston, MA 02114
(“HOSPITAL”). This AGREEMENT replaces the Exclusive License Agreement, MGH Agreement No. 2004A18936, dated and effective May 17, 2005, (“EFFECTIVE DATE”) and any subsequent amendments including an Amendment No. 1
effective as of January 23, 2006, between HOSPITAL and JUNIPER, and an Amendment No. 2 effective as of May 17, 2010, between HOSPITAL and COMPANY (collectively the “ORIGINAL AGREEMENT”). 

RECITALS 

WHEREAS, under research programs funded by the HOSPITAL and the U.S. Government, HOSPITAL through research conducted by Drs. Richard Rox
Anderson and Dieter Manstein (“INVESTIGATORS”) has developed inventions pertaining to the use of cooling to treat human fat and devices and methods related thereto; 

WHEREAS, HOSPITAL, as a center for patient care, research and education, is the owner of certain PATENT RIGHTS (defined below) and
desires to grant a license of those PATENT RIGHTS to COMPANY in order to benefit the public by disseminating the results of its research via the commercial development, manufacture, distribution and use of products and processes. 

WHEREAS, COMPANY has the capability to commercially develop, manufacture and use PRODUCTS and PROCESSES (defined below) for public use
and benefit and desires to license such PATENT RIGHTS. 

 For good and valuable consideration, the sufficiency of which is hereby acknowledged, the
PARTIES hereto agree as follows: 
 1. CERTAIN DEFINITIONS 

The following terms shall have the following meanings as used herein, unless the context requires otherwise. 

1.1 “510(k) APPLICATION” shall mean a pre-market notification, or 510(k) application under section 510(k) of the FD&C. 

1.2 “ACCESSORY PRODUCT” shall mean any disposable product (i.e., product for single or limited time use) or software which, while not
itself a PATENT PRODUCT, is TRANSFERRED for use in conjunction with a PATENT PRODUCT or performance of a PATENT PROCESS. 
 1.3
“ACCESSORY PROCESS” shall mean any per-procedure fee or service fee payable by a customer or end-user to COMPANY for use of a PATENT PRODUCT or performance of the PATENT PROCESS. 

1.4 “AFFILIATE” with respect to either PARTY shall mean any corporation or other legal entity other than that PARTY in whatever country
organized, controlling, controlled by or under common control with that PARTY. The term “control” shall mean (a) in the case of COMPANY, direct or indirect ownership of more then fifty percent (50%) of the voting securities
having the right to elect directors, and (b) in the case of HOSPITAL, the power, direct or indirect, to elect or appoint more than fifty percent (50%) of the directors or trustees, or to cause direction of management and policies, whether
through the ownership of voting securities, by contract or otherwise. 
 1.5 “CHANGE OF CONTROL” shall occur upon the first
public sale of the COMPANY’s stock under an effective registration statement following the COMPANY’s IPO; or upon the sale or other transfer to a third party of all or substantially all of the COMPANY’s assets; or upon a merger or
consolidation of COMPANY with a third party which results in the voting securities of COMPANY outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving entity
immediately after such merger or consolidation; or upon the sale of more than fifty percent (50%) of COMPANY stock (not including a bona fide equity financing in which COMPANY issues new shares of its stock). 

1.6 “CLAIM(S)” shall mean any pending or issued claim(s) of any PATENT RIGHT that has not been permanently revoked, nor held
unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through
reissue, disclaimer or otherwise. 
 1.7 “COMMERCIAL SALE” shall mean any TRANSFER of a PRODUCT or PROCESS by COMPANY, an
AFFILIATE or SUBLICENSEE (which may include a TRANSFER to an AFFILIATE or SUBLICENSEE for value in the form of cash or otherwise.) 

  
 Frazier-MGH License
Agreement, Execution Version 
 2 
  

 1.7A “DISTRIBUTOR INCOME” shall mean any and all income or amounts, including the fair
market value of any non-monetary consideration, actually received by COMPANY, its AFFILIATES and SUBLICENSEES for the TRANSFER of PRODUCTS or PROCESSES to a third party distributor who is not an AFFILIATE or SUBLICENSEE in consideration of the right
to further TRANSFER a PRODUCT or PROCESS by such third party distributor to an end user. Such DISTRIBUTOR INCOME shall expressly exclude any SUBLICENSE INCOME as such term is defined in Section 1.24 of this AGREEMENT. 

1.8 “FDA” shall mean the United States Food and Drug Administration. 
 1.9 “FD&C” shall mean the Federal Food, Drug and Cosmetic Act, as amended. 

1.10 “IDE” shall mean Investigational Device Exemption, as such term is used in the FD&C. 

1.11 “IPO” shall mean the first firm underwritten public offering of the COMPANY’s common stock under the Securities Act of 1933.

 1.12 “LICENSE FIELD” shall mean removal of cutaneous, subcutaneous or subdermal fat, treatment or removal of cellulite, and
any therapy or procedures (including without limitation aesthetic therapies or procedures) to the tissues and structures of the skin (including without limitation sweat glands and hair follicles), subcutaneous tissue, and tumors, lesions and adipose
tissue of the skin and of subdermal tissue. 
 1.13 “LICENSE TERM” shall mean the period commencing on the EFFECTIVE DATE and
continuing, with respect to any PATENT RIGHTS, for the life of the applicable patent, and, with respect to any TECHNOLOGICAL INFORMATION, in perpetuity. 
 1.14 “LICENSE TERRITORY” shall mean worldwide, with the following regions referred to as the “PRIMARY REGIONS”: (i) the United States, (ii) Japan, and
(iii) EUROPE. “EUROPE” shall mean the following countries in Europe: France, Germany and the United Kingdom. 
 1.15
“NET SALES” shall mean: 
  

	 	(a)	the greatest of the gross amount billed, invoiced or received by COMPANY, its AFFILIATES and SUBLICENSEES (for the purposes of this Section 1.15 each a
“SELLER”) for COMMERCIAL SALES of PRODUCTS and PROCESSES by COMPANY, its AFFILIATES and SUBLICENSEES (but excluding (i) any amounts billed, invoiced or received resulting from any TRANSFER of any PRODUCT or PROCESS between or among
COMPANY, an AFFILIATE or any SUBLICENSEE, unless the transferee is the final purchaser of such PRODUCT or PROCESS; (ii) any royalty or similar payment by a SUBLICENSEE to COMPANY or an AFFILIATE, or by an AFFILIATE to COMPANY, on account of a
TRANSFER of any PRODUCT or PROCESS by a SUBLICENSEE or AFFILIATE, as the case may be, to a third party; and (iii) any DISTRIBUTOR INCOME), less (to the extent appropriately documented) the following amounts actually paid or otherwise
incurred by SELLER in effecting such TRANSFER: 

  

	 	(i)	credits and allowances by reason of rejection or return; 

  
 Frazier-MGH License
Agreement, Execution Version 
 3 
  

	 	(ii)	reasonable and customary rebates, discounts and chargebacks; 

  

	 	(iii)	amounts for outbound transportation, insurance, handling and shipping, to the extent separately invoiced; and 

 

	 	(iv)	taxes, customs duties and other governmental charges levied on or measured by the sale, transportation, import or delivery of PRODUCTS or PROCESSES, to the extent
separately invoiced, whether paid by or on behalf of COMPANY so long as COMPANY’s price is reduced thereby, but not franchise or income taxes of any kind whatsoever. 

 

	 	(b)	In addition to the deductions listed in subsections 1.15(a)(i)-(iv) above, NET SALES in a REPORTING PERIOD will be reduced by the amount of bad debt remaining
uncollected from TRANSFERS in previous REPORTING PERIODS, where COMPANY has previously paid royalties to HOSPITAL with respect to the COMMERCIAL SALE giving rise to the debt, and COMPANY has used reasonable best efforts to collect such debt and no
longer has a reasonable expectation of collecting the invoiced amount. 

  

	 	(c)	No deductions shall be made for commissions paid to individuals whether they be with independent sales agencies or employed by a SELLER or otherwise, or for any cost of
collections. 

  

	 	(d)	NET SALES shall occur on the earlier of the date of billing or invoicing for TRANSFER of a PRODUCT or PROCESS. For a PRODUCT or PROCESS for which SELLER does not bill
or invoice, NET SALES shall occur on the date on which payment is due or made to the SELLER, whichever is earlier. If the date on which such payment is due or made cannot be ascertained, NET SALES shall be deemed to have occurred on the date of the
TRANSFER of the PRODUCT or PROCESS. 

  

	 	(e)	In the event that a SELLER TRANSFERS any PRODUCT or PROCESS at a discounted price that is lower than a reasonable and customary discount permitted under
Section 1.15(a)(ii) above, or for non-cash consideration (whether or not at a discount), NET SALES shall be calculated based on the average non-discounted (except as provided in Section 1.15(a)(ii) above) cash amount charged to an
independent third party for the same PRODUCT or PROCESS during the same REPORTING PERIOD or, in the absence of such transaction, on the fair market value of the PRODUCT or PROCESS. Notwithstanding the foregoing or any other provision of this
Section 1.15(a)-(f), NET SALES shall not include the TRANSFER of any PRODUCT or PROCESS by a SELLER (i) for use in any clinical trial or any preclinical or other research, or (ii) for use to promote additional NET SALES, including use
of detailing samples and promotional offers, except to the extent that such TRANSFERS as provided in Section 1.15(e)(ii) shall not exceed more than 1% of the total PRODUCT or PROCESS TRANSFERRED during the same REPORTING PERIOD.

  
 Frazier-MGH License
Agreement, Execution Version 
 4 
  

	 	(f)	In the case of a TRANSFER of a PRODUCT within COMPANY or between or among COMPANY, any AFFILIATE or SUBLICENSEE, solely for further TRANSFER by such transferee, NET
SALES shall be based on the further TRANSFER of such PRODUCT by such transferee. 

 1.16 “PATENT RIGHTS” shall
mean the United States and international patent application(s) and patent(s) listed in Appendix A or the equivalent of such applications including any division, continuations, and those claims in any continuations-in-part of the aforementioned
patent applications which claim an invention described or claimed in said patent application and are entitled to the priority filing date of the said patent application, or substitute therefor, or any foreign patent application corresponding to any
such patent applications, or any U.S. or foreign letters patent or the equivalent thereof issuing thereon, or any reissue, renewal, reexamination or extension thereof. 
 1.17 “PMA APPLICATION” shall mean a pre-market approval application under section 515 of the FD&C. 
 1.18 “PATENT PROCESS” shall mean any process, method or service the use or performance of which, in whole or in part, absent the license granted hereunder would infringe, or is covered by
one or more CLAIM(S) within the PATENT RIGHTS. 
 1.19 “PATENT PRODUCT” shall mean any article, device or composition, the
manufacture, use, or sale of which, in whole or in part absent the license granted hereunder would infringe, or is covered by, one or more CLAIM(S) within the PATENT RIGHTS. 
 1.20 “PROCESS” shall mean any ACCESSORY PROCESS and/or PATENT PROCESS. 
 1.21
“PRODUCT” shall mean any ACCESSORY PRODUCT and/or PATENT PRODUCT. 
 1.22 “REPORTING PERIOD” shall mean each
three month period ending March 31, June 30, September 30 and December 31. 
 1.23 “SUBLICENSEE”
shall mean any third party sublicensee of the rights granted by COMPANY under Section 2.1(a)(iii). 
 1.24 “SUBLICENSING
INCOME” shall mean any and all non-royalty income received by COMPANY or an AFFILIATE in consideration for the sublicensing of any license granted to COMPANY by HOSPITAL hereunder or distribution of any PRODUCT or PROCESS by a SUBLICENSEE
or a third party distributor who is not an AFFILIATE or SUBLICENSEE, including but not limited to up front license fees, license issue fees, maintenance fees, payments pertaining to distribution rights, milestone payments or the fair market value of
any non-cash consideration, but not including DISTRIBUTOR INCOME or payments that COMPANY receives for direct research and development or for equity investments in, or extensions of credit to COMPANY. 

  
 Frazier-MGH License
Agreement, Execution Version 
 5 
  

 1.25 “TECHNOLOGICAL INFORMATION” shall mean any research data, designs, formulae, know-how,
process information and other information that is known to Dieter Manstein and Rox Anderson as of the EFFECTIVE DATE of the AGREEMENT, is owned or controlled by HOSPITAL and is necessary or useful for the development or commercialization of PRODUCTS
or PROCESSES. 
 1.26 “TRANSFER” shall mean to sell or have sold, to lease or have leased, to import or have imported or
otherwise to transfer or have transferred, for value in the form of cash or otherwise, a PRODUCT or PROCESS, and further in the case of a PROCESS to use or perform such PROCESS for the benefit of a third party. 

1.27 “DISTRIBUTION 510(k) or PMA APPLICATION”shall mean a 510(k) or PMA APPLICATION that is filed by the COMPANY with the United States Food
and Drug Administration with the intent to make available for distribution a PRODUCT in the United States. For purposes of this Section 1.27, manufacturing scale-up of a PRODUCT for distribution shall be deemed as “intent to make available
for distribution a PRODUCT”. 
 2. LICENSE 
 2.1 Grant of License. 
  

	 	(a)	Subject to the terms of this AGREEMENT, HOSPITAL hereby grants to COMPANY in the LICENSE FIELD in the LICENSE TERRITORY for the LICENSE TERM: 

 

	 	(i)	an exclusive, royalty-bearing license under PATENT RIGHTS to make, have made, use, have used, sell, offer to sell, have sold, and TRANSFER PRODUCTS and to use, have
used, otherwise practice and have practiced and TRANSFER PROCESSES; 

  

	 	(ii)	the nonexclusive right to disclose, use and transfer TECHNOLOGICAL INFORMATION disclosed by HOSPITAL to COMPANY hereunder; and 

 

	 	(iii)	the right to grant sublicenses under the rights granted in Section 2.1(a)(i) and 2.1(a)(ii) to SUBLICENSEES, provided that in each case COMPANY shall be
responsible for the performance of any obligations of SUBLICENSEES relevant to this AGREEMENT as if such performance were carried out by COMPANY itself, including, without limitation, the payment of any royalties or other payments provided for
hereunder, regardless of whether the terms of any sublicense provide for such amounts to be paid by the SUBLICENSEE directly to HOSPITAL. 

  

	 	(b)	The licenses granted in Section 2.1(a) above include the right to grant to the purchaser of PRODUCTS from COMPANY, AFFILIATES and SUBLICENSEES the right to use
such purchased PRODUCTS in a method coming within the scope of PATENT RIGHTS and TECHNOLOGICAL INFORMATION. 

  
 Frazier-MGH License
Agreement, Execution Version 
 6 

	 	(c)	The foregoing license grant shall include the grant of said license to any AFFILIATE of COMPANY, provided that such AFFILIATE shall assume the same obligations as those
of COMPANY and be subject to the same terms and conditions hereunder and further provided that COMPANY shall be responsible for the performance by said AFFILIATE of said obligations and for compliance by said AFFILIATE with said terms and
conditions. COMPANY shall provide to HOSPITAL a fully signed, non-redacted copy of each agreement with each AFFILIATE that assumes the aforesaid obligations, including all exhibits, attachments and related documents and any amendments, within thirty
(30) days of request by HOSPITAL. 

 2.2 Sublicenses. All sublicenses granted hereunder shall be consistent with the
terms of this AGREEMENT and shall incorporate terms and conditions sufficient to enable COMPANY to comply with this AGREEMENT. COMPANY shall provide to HOSPITAL a fully signed non-redacted copy of all sublicense agreements and amendments thereto,
including all exhibits, attachments and related documents, within thirty (30) days of executing the same. Upon termination of this AGREEMENT or any license granted hereunder for any reason, any sublicenses shall be addressed in accordance with
Section 10.6. 
 2.3 Retained Rights; Requirements. Any and all licenses granted hereunder are subject to: 

 

	 	(a)	HOSPITAL’s and HOSPITAL’s AFFILIATES’ right to make and to use the subject matter described and/or claimed in the PATENT RIGHTS and to permit others at
academic, government and not-for-profit institutions to make and use the subject matter described and/or claimed in PATENT RIGHTS for research and educational purposes; and 

 

	 	(b)	for PATENT RIGHTS supported by federal funding, the rights, conditions and limitations imposed by U.S. law (see 35 U.S.C. § 202 et seq. and
regulations pertaining thereto), including without limitation: 

  

	 	(i)	the royalty-free non-exclusive license granted to the U.S. government; and 

 

	 	(ii)	the requirement that any PRODUCTS used or sold in the United States shall be manufactured substantially in the United States. 

2.4 No Additional Rights. It is understood that nothing in this AGREEMENT shall be construed to grant COMPANY a license express or implied under
any patent owned solely or jointly by HOSPITAL other than the PATENT RIGHTS expressly licensed hereunder. HOSPITAL shall have the right to license any PATENT RIGHTS to any other party for any purpose outside of the LICENSE FIELD or the LICENSE
TERRITORY. 

  
 Frazier-MGH License
Agreement, Execution Version 
 7 

 2.5 Disclosure of TECHNOLOGICAL INFORMATION. At COMPANY’s request, HOSPITAL (through Drs.
Anderson and Manstein) shall use reasonable efforts to disclose within sixty (60) days after execution of this AGREEMENT any TECHNOLOGICAL INFORMATION beyond that disclosed in the patent application for the PATENT RIGHTS which is then known to
Drs. Anderson and Manstein and which is reasonably necessary for COMPANY to utilize the licenses granted hereunder. 
 2.6 Right of
Review. To provide COMPANY with the opportunity to seek further licenses if so desired, HOSPITAL shall, for a period of five (5) years from the EFFECTIVE DATE of this AGREEMENT, use reasonable efforts to notify COMPANY of disclosures for
patentable inventions in the LICENSE FIELD from INVESTIGATORS’ laboratory or laboratories, except to the extent that such disclosures for patentable inventions are sponsored by a third party or subject to any obligations to a third party. Upon
COMPANY’s request, HOSPITAL shall enter into good faith negotiation with COMPANY for a license under patent applications claiming such inventions. 
 3. DUE DILIGENCE OBLIGATIONS 
 3.1 Diligence Requirements. COMPANY shall itself use,
or shall cause its AFFILIATES or SUBLICENSEES, as applicable, to use, reasonable efforts to develop and make available to the public PRODUCTS and PROCESSES throughout the LICENSE TERRITORY in the LICENSE FIELD. Such efforts shall include achieving
the following objectives within the time periods designated below following the EFFECTIVE DATE: 
  

	 	(a)	Pre-Sales Requirements. 

  

	 	(i)	within six (6) months, initiate development of a prototype PRODUCT in COMPANY’s facilities and initiate animal testing with a prototype;

  

	 	(ii)	within nine (9) months, complete at least one animal of an animal study and prepare a clinical trial protocol; 

 

	 	(iii)	within sixteen (18) months, submit a protocol to the appropriate regulatory body, or to an IRB or similar body, to initiate human feasibility study;

  

	 	(iv)	within eighteen (18) months, provide HOSPITAL with a written report outlining COMPANY’s plan for its pursuit and acquisition of regulatory approval to market
the PRODUCTS and/or PROCESSES in the United States; 

  

	 	(v)	within thirty six (36) months, submit a protocol for the first pivotal clinical trial under an IDE; 

  
 Frazier-MGH License
Agreement, Execution Version 
 8 

	 	(vi)	within thirty six (36) months, provide HOSPITAL with a written report outlining COMPANY’s plan for its pursuit and acquisition of regulatory clearance or
approval to market the PRODUCTS and/or PROCESSES in the PRIMARY REGIONS; and 

  

	 	(vii)	at COMPANY’s sole discretion, file with the FDA either (1) a 510(k) APPLICATION within forty eight (48) months, or (2) a PMA APPLICATION within
fifty four (54) months. 

  

	 	(b)	Post-Sales Requirements. 

  

	 	(i)	Following the first COMMERCIAL SALE in any PRIMARY REGION in the LICENSE TERRITORY, COMPANY shall itself or through its AFFILIATES and/or SUBLICENSEES make continuing
COMMERCIAL SALES in such PRIMARY REGION without any elapsed consecutive time period of one (1) year or more in which such COMMERCIAL SALES do not occur; 

 

	 	(ii)	COMPANY shall itself or through an AFFILIATE or SUBLICENSEE make such first COMMERCIAL SALE within the following countries and regions in the LICENSE TERRITORY within
the following number years after the EFFECTIVE DATE of this AGREEMENT: 

  

			
	United States of America	    	Six (6) years
	Japan	    	Seven (7) years
	Latin America	    	Seven (7) years
	EPO	    	Seven (7) years

 Achievement of the foregoing objectives shall be deemed to satisfy COMPANY’s obligations to use reasonable
efforts under this Section 3.1. 
 3.2 Diligence Failures. If HOSPITAL determines that COMPANY has failed to fulfill
any of its obligations under Section 3.1 then HOSPITAL may treat such failure as a default and may terminate this AGREEMENT and/or the licenses granted hereunder in accordance with Section 10.4, provided, however, that in the event that
COMPANY reasonably believes that it may fail to meet any of its obligations under Section 3.1 above due to circumstances that COMPANY could not have reasonably avoided, such as technical difficulties or delays in pre-clinical or clinical
studies or regulatory processes, and COMPANY notifies HOSPITAL of such anticipated failure at least thirty (30) days in advance of such milestone, COMPANY may request a reasonable extension for such milestone, which HOSPITAL shall consider in
good faith. Any grant of a milestone extension shall be at HOSPITAL’s sole discretion, provided that if in HOSPITAL’s sole judgment COMPANY has made commercially reasonable efforts to meet its obligations under Section 3.1, the grant
of such milestone extension shall not be unreasonably withheld. 
 3.3 Diligence Reports. COMPANY shall provide all reports
with respect to its obligations under Section 3.1 as set forth in Section 5. 

  
 Frazier-MGH License
Agreement, Execution Version 
 9 

 4. PAYMENTS AND ROYALTIES 
 4.1 License Issue Fee. COMPANY shall pay HOSPITAL a one-time, non-refundable license issue fee in the sum of Two Hundred and Fifty Thousand Dollars ($250,000 U.S. Dollars) upon the earlier of
(i) the close of the first round of financing or (ii) thirty (30) days of the execution of the ORIGINAL AGREEMENT. 
 4.2
Patent Cost Reimbursement. COMPANY shall reimburse HOSPITAL for all costs associated with the preparation, filing, prosecution and maintenance of all PATENT RIGHTS (“PATENT COSTS”). As of the EFFECTIVE DATE, HOSPITAL has incurred
approximately One hundred and fourteen Thousand Dollars ($114,000 U.S. Dollars) in PATENT COSTS, which amount COMPANY shall pay to HOSPITAL upon the earlier of (i) the close of the first round of financing or (ii) thirty (30) days of
the execution of the ORIGINAL AGREEMENT. In addition, COMPANY shall pay to HOSPITAL, or at HOSPITAL’s request directly to patent counsel, all other PATENT COSTS within thirty (30) days of COMPANY’s receipt of an invoice for such
PATENT COSTS either from HOSPITAL or HOSPITAL’s patent counsel. COMPANY agrees to indemnify, defend and hold HOSPITAL harmless from and against any and all liabilities, damages, costs and expenses arising from the failure of Company to timely
pay such invoices and PATENT COSTS. HOSPITAL shall instruct its patent counsel to provide copies of all invoices detailing PATENT COSTS to HOSPITAL for HOSPITAL’s administrative files and to COMPANY. 

4.3 License Maintenance Royalty. COMPANY shall pay to HOSPITAL the following amounts as minimum annual license maintenance royalty payments within
thirty (30) days after the end of the REPORTING PERIOD in which each of the following anniversaries of the EFFECTIVE DATE occurs: 
  

	 	(a)	Seventy Five Thousand Dollars ($75,000 U.S. Dollars) on the first anniversary of the EFFECTIVE DATE following the first COMMERCIAL SALE. 

 

	 	(b)	One Hundred Thousand Dollars ($100,000 U.S. Dollars) on the second anniversary of the EFFECTIVE DATE following the first COMMERCIAL SALE. 

 

	 	(c)	One Hundred and Fifty Thousand Dollars ($150,000 U.S. Dollars) on the third anniversary of the EFFECTIVE DATE following the first COMMERCIAL SALE.

  

	 	(d)	Two Hundred Thousand Dollars ($200,000 (U.S. Dollars) on the third anniversary of the EFFECTIVE DATE following the first COMMERCIAL SALE, and on each subsequent
anniversary of the EFFECTIVE DATE thereafter until the end of LICENSE TERM. 

  
 Frazier-MGH License
Agreement, Execution Version 
 10 

 The annual license maintenance royalty is nonrefundable; however, it shall be credited
against royalties due on NET SALES and DISTRIBUTOR INCOME made during the same calendar year as such annual license maintenance royalty payment is due as provided in Sections 4.3(a)-4.3 (d) above, if any. However the annual license maintenance
royalty shall not be credited against royalties due on NET SALES and DISTRIBUTOR INCOME made in any other year. 
 4.4 Milestone
Payments. In addition to the payments set forth in Sections 4.1 through 4.3 above, COMPANY shall pay HOSPITAL milestone payments as follows: 
  

			
	 4.4(a)
	  	 One Million Fifty Thousand Dollars ($1,050,000 U.S. Dollars) upon the earlier of January 5, 2011 or receiving FDA clearance or approval of the submission
titled REQUEST FOR EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR THE ZELTIQTM DERMAL COOLING DEVICE and dated October 14, 2009.

		
	 4.4(b)
	  	One Million Dollars ($1,000,000 U.S. Dollars) within forty-five (45) days of reaching cumulative worldwide NET SALES of PRODUCTS and PROCESSES in the amount of Seventy
Million Dollars ($70,000,000 U.S. Dollars).
		
	 4.4(c)
	  	 Six Million Dollars ($6,000,000 U.S. Dollars) within forty-five (45) days of the earlier of:

 

(i)     reaching cumulative worldwide NET SALES of PRODUCTS and
PROCESSES in the amount of Two Hundred Million Dollars ($200,000,000 U.S. Dollars);
  
 provided however, if at the time the COMPANY reaches cumulative worldwide NET SALES of PRODUCTS and PROCESSES in the amount of Two Hundred Million Dollars ($200,000,000 U.S. Dollars) a CHANGE OF CONTROL
has not yet occurred and the Company is still privately held, then payment of the amount specified above in this 4.4(c) shall be made in two installments: the first installment of Three Million Dollars ($3,000,000 U.S. Dollars) shall be made within
45 days after the COMPANY reaches Two Hundred Million Dollars ($200,000,000 U.S. Dollars) in cumulative worldwide NET SALES; the second installment of Three Million Dollars ($3,000,000 U.S. Dollars) shall be made exactly one (1) year thereafter;
or

  
 Frazier-MGH License
Agreement, Execution Version 
 11 

			
		 	 (ii)    first CHANGE OF CONTROL

 
 provided however, if at the time such CHANGE OF CONTROL occurs,

 

1)       if the CHANGE OF CONTROL is not an IPO, and the total
consideration paid for all of the assets or shares of the Company is less than the sum of the aggregate invested capital invested in the COMPANY from inception, plus Six Million Dollars ($6,000,000 U.S. Dollars); or

 

2)       if the CHANGE OF CONTROL is an IPO, and the price per
share at which the shares are offered to the public reflects a pre-money valuation of the COMPANY that is less than the sum of the aggregate capital invested in the COMPANY from inception, plus Six Million Dollars ($6,000,000 U.S.
Dollars);
  
 then, the milestone payment in
4.4(c) is payable only if and when the Company or its successor reaches cumulative worldwide NET SALES of PRODUCTS and PROCESSES in the amount of Two Hundred Million Dollars ($200,000,000 U.S. Dollars) as provided in 4.4(c)(i) above.

 
 As of the date of this Agreement, the aggregate invested
capital in the COMPANY from its inception is approximately Seventy-eight Million Dollars ($78,000,000 U.S. Dollars) and the number of fully diluted shares outstanding as of June 30, 2011 is approximately 112,000,000. For purposes of
illustration only, based on the invested capital and the number of fully diluted shares described above in this paragraph, an IPO would have to be priced at approximately $0.75 per share or more for the milestone payment described in Section 4.4(c)
to be payable within forty five (45) days after such IPO. An example calculation is as follows:
  

  $78.0M

+$ 6.0M
   $84.0M
  
 /112M shares
 $0.75/share

  
 Frazier-MGH License
Agreement, Execution Version 
 12 

 Aggregate stock issuance to HOSPITAL discussed below shall not exceed in the aggregate 3.5%
of fully-diluted equity of the COMPANY. 
 COMPANY shall notify HOSPITAL of the achievement of the One Million Fifty Thousand
Dollar ($1,050,000 U.S. Dollars) milestone, the One Million Dollar ($1,000,000 U.S. Dollars) milestone, and the Six Million Dollar ($6,000,000 U.S. Dollars) milestone set forth in Sections 4.4(a)-(c), respectively. HOSPITAL may elect to receive up
to 50% of any of amounts due under subsections (b) and (c) above in COMPANY common stock or non-voting SPECIAL PREFERRED STOCK (as defined below), at such time as COMPANY achieves such milestones, by (i) notifying the COMPANY in
writing of such election within thirty (30) days of notification by COMPANY of COMPANY’s achievement of such milestone, and (ii) agreeing to customary restrictions and representations required, in the reasonable opinion of
COMPANY’s legal counsel, to comply with the rules and regulations promulgated by the United States Securities and Exchange Commission and other applicable laws. In the event that HOSPITAL elects to receive any of the aforementioned amounts due
under subsections (b) and (c) above in COMPANY stock, COMPANY shall use commercially reasonable efforts to obtain any required consents and/or waivers, within thirty (30) days from receipt of HOSPITAL’s notice, to authorize such
share of COMPANY common stock or Special Preferred Stock and to effectuate such COMPANY stock issuance, which period may be extended as mutually agreed to by the PARTIES in writing. Any Special Preferred Stock issued to HOSPITAL pursuant to this
Section 4.4 shall be issued upon the same terms and conditions as provided to investors of the round of financing immediately prior to such milestone payment (except that such shares shall be non-voting), and valued at the per share price set
forth in the most recent of (i) a last round of financing or (ii) an independent valuation (performed annually in accordance with IRS guidelines) (such shares, once authorized, the “SPECIAL PREFERRED STOCK”). 

Once COMPANY has made any particular milestone payment under Section 4.4, COMPANY will not be obligated to make any payment under
Section 4.4 with respect to the re-occurrence of the same milestone. For example, the milestone payments in Sections 4.4(a)-(c) are one-time payments for only the first occurrence of each such milestone, as opposed to annual milestone
payments based on annual NET SALES of PRODUCTS and/or PROCESSES in the United States. 
 In the event that COMPANY achieves any of the foregoing
milestones through a SUBLICENSEE, and the sublicense agreement with such SUBLICENSEE provides for a milestone payment for such milestone event, which payment also meets the definition of SUBLICENSING INCOME under Section 4.6, COMPANY shall
first pay HOSPITAL the milestone payment as payable hereinabove. In the event that the amount of SUBLICENSE INCOME associated with the achievement of such milestone exceeds the amount payable to HOSPITAL for achievement of such milestone as set
forth above, then COMPANY shall also pay the appropriate percentage of the excess as a non-royalty SUBLICENSE INCOME payment, as provided in Section 4.6 below. For example, in the event that COMPANY meets its milestone obligation in
Section 4.4(b) through a SUBLICENSEE’s achievement of such milestone, and such SUBLICENSEE’s sublicense agreement with COMPANY provides for payment by 

  
 Frazier-MGH License
Agreement, Execution Version 
 13 

 
SUBLICENSEE of a One Million Five Hundred Thousand Dollar ($1,500,000 U.S. Dollars) milestone payment to COMPANY on the same event as described in Section 4.4(b), the COMPANY shall first pay
HOSPITAL the One Million Dollar ($1,000,000 U.S. Dollars) payment as provided in Section 4.4(b), and shall then pay 50% of the remaining Five Hundred Thousand Dollar ($500,000 U.S. Dollars) SUBLICENSING INCOME as provided in Section 4.6(a)
below. 
 4.5 Royalties. 
  

	 	(a)	Beginning with the first COMMERCIAL SALE in any country in the LICENSE TERRITORY, and subject to Section 4.5(d) below, COMPANY shall pay HOSPITAL during the
term of the license granted under Section 2.1(a)(i), a royalty of seven percent (7%) of (i) the NET SALES of all PRODUCTS and PROCESSES and (ii) any DISTRIBUTOR INCOME. 

 

	 	(b)	If more than one royalty rate is applicable to a PRODUCT or PROCESS, only the highest of the applicable royalty rates shall apply. 

 

	 	(c)	Except as otherwise provided in Section 4.5(d) of this AGREEMENT, COMPANY may offset 50% of any royalty payments COMPANY is legally obligated to make to third
parties to use patent rights that (i) dominate a PATENT RIGHT; or (ii) are necessary to commercialize the fat cooling mechanism of the device component of a PRODUCT. The amounts payable to HOSPITAL will not be reduced to less than 4% of
NET SALES and DISTRIBUTOR INCOME in a reporting period, and any amounts that are not offset during that period will not be offset in future periods. As used in this subsection 4.5(c): (i) “legally obligated” means obligated by court
order, settlement agreement, contract or other legally binding written commitment; (ii) a PATENT RIGHT is dominated if, in COMPANY’s reasonable judgment, it cannot reasonably be practiced without infringing a valid claim of the dominant
patent; and (iii) “necessary to commercialize” means reasonably necessary to make available for COMMERCIAL SALE on a commercially reasonable basis. For purposes of clarification, this section 4.5(c) shall not apply to any royalty
payments that COMPANY may be obligated to make according to the ROYALTY OFFSET AGREEMENT between HOSPITAL and COMPANY entered into concurrently with this AGREEMENT, but shall apply to other royalty payments COMPANY is obligated to make to third
parties whether COMPANY’s royalty obligations to HOSPITAL are determined in accordance with Section 4.5(a) or Section 4.5(d) below. 

  

	 	(d)	In the event that COMPANY is obligated to make royalty payments according to the ROYALTY OFFSET AGREEMENT between HOSPITAL and COMPANY, COMPANY’s royalty
obligations to HOSPITAL shall be as set forth in the ROYALTY OFFSET AGREEMENT entered into concurrently with this AGREEMENT. 

  

	 	(e)	 If at any time during the term of this AGREEMENT, one or more competitors introduce in any country a product that competes with an ACCESSORY PRODUCT,

  
 Frazier-MGH License
Agreement, Execution Version 
 14 

	 	 
then the PARTIES in good faith shall promptly review the facts and circumstances, and, if appropriate, negotiate an equitable adjustment to the royalty rate on NET SALES of such ACCESSORY
PRODUCTS. 

  

	 	(f)	All payments due to HOSPITAL under this Section 4.5 shall be due and payable by COMPANY within thirty (30) days after the end of each REPORTING PERIOD, and
shall be accompanied by a report as set forth in Section 5.4. 

 4.6 Non-Royalty Income. COMPANY shall pay HOSPITAL
within thirty (30) days after the end of each REPORTING PERIOD the following percentages of any and all non-royalty SUBLICENSING INCOME attributable to the PRODUCT or PROCESS, that COMPANY receives: 

 

	 	(a)	50% of any SUBLICENSING INCOME received if a sublicense is executed before the earlier of the submission of the first IDE for a PRODUCT or PROCESS or filing for the
first FDA marketing approval of a PRODUCT or PROCESS. 

  

	 	(b)	35% of any SUBLICENSING INCOME received if a sublicense is executed after the earlier of the submission of the first IDE for a PRODUCT or PROCESS or filing for the
first FDA marketing approval of a PRODUCT or PROCESS, but prior to the receipt of the first FDA marketing approval of a PRODUCT or PROCESS. 

  

	 	(c)	20% of any SUBLICENSING INCOME received if a sublicense is executed after receipt of the first FDA marketing approval of a PRODUCT or PROCESS. 

4.7 Buydown Option. 
  

	 	(a)	COMPANY may, at any time following the date that is thirty-six (36) months after the first payment by COMPANY of royalties pursuant to Section 4.5 above,
request a buydown of all or a portion of future royalty payments to HOSPITAL by (1) delivery to HOSPITAL of a written notice requesting a valuation of such buydown (the “Valuation Request”), and (2) following receipt of the
Valuation (as defined below), delivery to HOSPITAL of a written notice of its intent to exercise the buydown (the “Buydown Notice”). Upon delivery to HOSPITAL of the Valuation Request, the PARTIES agree to proceed in accordance with
Sections 4.7(b) and (c) below. 

  

	 	(b)	The Valuation shall be determined by mutual agreement of the PARTIES or, if no such agreement is reached within thirty (30) days following the delivery of the
Valuation Request, the Valuation shall be determined by an appraisal process as follows: 

  

	 	(i)	 Selection of Appraisers. The PARTIES shall discuss in good faith and attempt to agree upon an investment banking or appraisal firm of recognized
national standing familiar with appraisal techniques (the 

  
 Frazier-MGH License
Agreement, Execution Version 
 15 

	 	 
“Appraiser”) within fifteen (15) days after the failure to reach agreement in accordance with the terms of clause (b) above. If the PARTIES are unable to agree on a single
Appraiser within such fifteen day period, then each PARTY shall, within fifteen (15) additional days, designate by written notice to the other an investment banking or appraisal firm of recognized national standing familiar with appraisal
techniques, and the firms designated by the PARTIES shall agree upon and jointly designate, by written notice to each PARTY, a third investment banking or appraisal firm of recognized national standing familiar with appraisal techniques who shall be
the Appraiser. 

  

	 	(ii)	Evaluation Procedures. The Appraiser shall be directed to determine the market value of the buydown (the “Valuation”) and deliver a certificate setting
forth its determination (the “Appraiser’s Certificate”) to each PARTY within forty-five (45) days after the date on which notice of the Appraiser’s selection is given to each PARTY. The Appraiser’s Certificate once
delivered may not be retracted or modified in any respect. 

  

	 	(iii)	Cooperation. The PARTIES will cooperate in providing the Appraiser with such information within their possession that may be reasonably requested by such
Appraiser for purposes of its evaluation hereunder. Each PARTY shall have full access to the Appraiser’s work papers and shall be entitled to make presentations to the Appraiser. COMPANY shall be responsible for paying reasonable costs of the
Appraiser. 

  

	 	(iv)	Conclusive Determination. The determination of the Valuation made pursuant to this Section 4.7 shall be final and, subject to Section 4.7(c) below,
binding on the PARTIES, shall not be appealable to or reviewable by any court or arbitrator, and may only be changed by mutual written agreement of the PARTIES. 

 

	 	(c)	Following receipt by the PARTIES of the Appraiser’s Certificate, COMPANY shall have sixty (60) days to exercise its right to buy down under this
Section 4.7(c) by delivery of the Buydown Notice to the HOSPITAL. COMPANY shall have the right, at its sole discretion, to buy down up to twenty five percent (25%) of the future royalty payments. COMPANY may request, and HOSPITAL shall
consider a request by COMPANY, to buy down a greater percentage of future royalties, provided however that any decision to allow COMPANY to buy down more than twenty five percent (25%) of future royalties shall be at HOSPITAL’s sole
discretion. If COMPANY elects to buy down pursuant to this Section 4.7, then the PARTIES shall prepare and execute appropriate documentation reflecting the buydown, and, upon payment of the Valuation amount, COMPANY’s obligations to make
royalty payments to HOSPITAL under Section 4.5 shall be reduced as provided in such appropriate documentation reflecting the buydown or shall terminate, as the case may be. 

  
 Frazier-MGH License
Agreement, Execution Version 
 16 

 4.8 Form of Payment. All payments due under this AGREEMENT shall be drawn on a United States bank and
shall be payable in United States dollars. Each payment shall reference this AGREEMENT and identify the obligation under this AGREEMENT that the payment satisfies. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate
existing in the United States, as reported in The Wall Street Journal, on the last working day of the applicable REPORTING PERIOD. Such payments shall be without deduction of exchange, collection or other charges, and, specifically, without
deduction of withholding or similar taxes or other government imposed fees or taxes, except as permitted in the definition of NET SALES. Checks for all payments due to the HOSPITAL under this AGREEMENT shall be made payable to HOSPITAL and addressed
as set forth in Section 12.2. Payments via wire transfer should be made as follows: 
 ABA [***] 

Account [***] 
 GHC Director’s Master Account 
 FleetBoston 

100 Federal Street 
 Boston, MA 02110 
 4.9 Overdue Payments. The payments due under this AGREEMENT (other than
payments that are the subject of a good faith dispute between COMPANY and HOSPITAL) shall, if overdue, bear interest beginning on the first day following the REPORTING PERIOD to which such payment was incurred and until payment thereof at a per
annum rate equal to two percent (2%) above the prime rate in effect on the due date as reported by The Wall Street Journal, such interest rate being compounded on the last day of each REPORTING PERIOD, not to exceed the maximum permitted by
law. Any such overdue payments when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not preclude HOSPITAL from exercising any other rights it may have as a consequence of the lateness
of any payment. 
 4.10 Board Seat Rights. HOSPITAL shall have the right to designate one board seat with full voting rights to the Board
of Directors of COMPANY until the earlier of two years after the EFFECTIVE DATE or the closing date of COMPANY’s second round of financing of at least Fifteen Million Dollars ($15,000,000 U.S. Dollars). For the period beginning on the earlier
of two years after the EFFECTIVE DATE or the closing date of COMPANY’s second round of financing of at least Fifteen Million Dollars ($15,000,000 U.S. Dollars), and ending four years after the EFFECTIVE DATE, COMPANY will fill that board seat
with an individual selected by COMPANY who is an employee of either HOSPITAL or Partners Healthcare System and is reasonably satisfactory to HOSPITAL. HOSPITAL shall, at its sole discretion, have the right to relinquish its right to designate one
board seat with full voting rights to the Board of Directors of COMPANY, at any time during the above four year period. In the event that HOSPITAL exercises such a right of relinquishment, HOSPITAL shall have the right to designate by notice to
COMPANY an individual reasonably satisfactory to COMPANY to attend meetings as a board observer, through the remainder of such four year period. The provisions of this Section 4.10 shall not apply after a CHANGE OF CONTROL. 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with
respect to the omitted portions. 

  
 Frazier-MGH License
Agreement, Execution Version 
 17 

 4.11 Further Definitions. For the purpose of this AGREEMENT and the ROYALTY OFFSET AGREEMENT and as
such terms are used in Sections 1.15 (NET SALES definition) and Section 4 of this AGREEMENT, the term PRODUCT shall mean any and all PATENT PRODUCT and ACCESSORY PRODUCT and the term PROCESS shall mean any and all PATENT PROCESS and ACCESSORY
PROCESS. 
 5. REPORTS AND RECORDS 
 5.1 Diligence Reports. Within sixty (60) days after the end of each calendar year, COMPANY shall report in writing to HOSPITAL on progress made toward the objectives set forth in
Section 3.1 during such preceding twelve (12) month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses
entered into and marketing. 
 5.2 Milestone Achievement Notification. COMPANY shall report to HOSPITAL the dates on which it achieves
the milestones set forth in Section 4.4 within thirty (30) days of each such occurrence. 
 5.3 Sublicensing Income Reports.
COMPANY shall, along with delivering payment as set forth in Section 4.6, report to HOSPITAL within thirty (30) days after the end of each REPORTING PERIOD, the amount of all SUBLICENSING INCOME received by COMPANY, and COMPANY’s
calculation of the amount due and paid to HOSPITAL from such income, including an itemized listing of the source of income comprising such consideration, and the name and address of each entity making such payments. 

5.4 COMMERCIAL SALES Reports. COMPANY shall report to HOSPITAL the date on which it achieves the first COMMERCIAL SALE in each country of the
LICENSE TERRITORY within thirty (30) days of each such occurrence. Following the first COMMERCIAL SALE, COMPANY shall deliver reports to HOSPITAL within thirty (30) days after the end of each REPORTING PERIOD. Each report under this
Section 5.4 shall have substantially the format outlined in Appendix B, shall be certified as correct by an officer of COMPANY and shall contain at least the following information as may be pertinent to a royalty accounting hereunder for the
immediately preceding REPORTING PERIOD: 
  

	 	(a)	the number of TRANSFERRED PRODUCTS and PROCESSES (broken down by PATENT PRODUCTS, PATENT PROCESSES, ACCESSORY PRODUCTS and ACCESSORY PROCESSES) by COMPANY, its
AFFILIATES and SUBLICENSEES in each country; 

  

	 	(b)	the gross amount billed, due and paid by COMPANY, its AFFILIATES and SUBLICENSEES for each PRODUCT and PROCESS (broken down by PATENT PRODUCTS, PATENT PROCESSES,
ACCESSORY PRODUCTS and ACCESSORY PROCESSES), in each country, and total billings or payments due or made for all PRODUCTS and PROCESSES; 

  
 Frazier-MGH License
Agreement, Execution Version 
 18 

	 	(c)	calculation of NET SALES and DISTRIBUTOR INCOME for the applicable REPORTING PERIOD in each country, including an itemized listing of permitted deductions;

  

	 	(d)	total royalties payable on NET SALES and DISTRIBUTOR INCOME in U.S. dollars, together with the exchange rates used for conversion; and 

 

	 	(e)	any other payments due to HOSPITAL under this AGREEMENT. 

 If no amounts are due to HOSPITAL for any REPORTING PERIOD, the report shall so state. 
 5.5
Audit Rights. COMPANY shall maintain, and shall cause each of its AFFILIATES and SUBLICENSEES to maintain, complete and accurate records relating to the rights and obligations under this AGREEMENT and any amounts payable to HOSPITAL in
relation to this AGREEMENT, which records shall contain sufficient information to permit HOSPITAL and its representatives to confirm the accuracy of any payments and reports delivered to HOSPITAL and compliance in all other respects with this
AGREEMENT. COMPANY shall retain and make available, and shall cause each of its AFFILIATES and SUBLICENSEES to retain and make available, such records for at least five (5) years following the end of the calendar year to which they pertain, to
HOSPITAL and/or its representatives, at HOSPITAL’s expense and upon at least fifteen (15) days’ advance written notice, for inspection during normal business hours at a mutually agreeable time, to verify any reports and payments made
and/or compliance in other respects under this AGREEMENT. If any examination conducted by HOSPITAL or its representatives pursuant to the provisions of this Section show an underreporting or underpayment of five percent (5%) or more in any
payment due to HOSPITAL hereunder, COMPANY shall bear the full cost of such audit and shall remit any amounts due to HOSPITAL (including interest due in accordance with Section 4.8) within thirty (30) days of receiving notice thereof from
HOSPITAL. 
 5.6 Treatment of Reports. All reports provided by COMPANY to HOSPITAL under this Section 5, and all information
obtained by HOSPITAL and/or HOSPITAL’s representatives under Section 5.5, shall be maintained in confidence by HOSPITAL, except as required by law. 
 6. PATENT PROSECUTION AND MAINTENANCE 
 6.1 Prosecution. HOSPITAL shall be
responsible for the preparation, filing, prosecution and maintenance of all patent applications and patents included in PATENT RIGHTS using independent patent counsel chosen by HOSPITAL and reasonably acceptable to COMPANY. If during the term of
this AGREEMENT COMPANY becomes dissatisfied with HOSPITAL’s independent patent counsel for any reasonable reason (whether related to the quality of their work, responsiveness, expense, or any other reasonable reason), HOSPITAL agrees to
consider COMPANY’s request to change patent counsel in good faith, and in the event that HOSPITAL agrees to such a change of patent counsel, to select new counsel of HOSPITAL’s choice which is reasonably acceptable to COMPANY. COMPANY
shall reimburse HOSPITAL for PATENT COSTS incurred by HOSPITAL relating thereto in accordance with Section 4.2. HOSPITAL shall not finally abandon any patent application for which COMPANY is bearing expenses without COMPANY’s consent.

  
 Frazier-MGH License
Agreement, Execution Version 
 19 
  

 6.2 Copies of Documents. With respect to any PATENT RIGHT, HOSPITAL shall, and shall instruct the
patent counsel prosecuting such PATENT RIGHT to, promptly copy COMPANY on all patent prosecution documents, submissions and correspondence, to keep both HOSPITAL and COMPANY fully informed of the progress of all patent applications and patents
included in the PATENT RIGHTS, and to give both HOSPITAL and COMPANY reasonable opportunity prior to making submissions to comment on the type and scope of claims, the nature of supporting disclosures, and other material matters. COMPANY’s
advice and suggestions shall be taken into reasonable consideration by HOSPITAL and its legal counsel in connection with such applications. 

6.3 COMPANY’s Election Not to Proceed. COMPANY may elect to surrender any patent or patent application in PATENT RIGHTS in any country upon
sixty (60) days advance written notice to HOSPITAL. Such notice shall relieve COMPANY from the obligation to pay for future PATENT COSTS relating to such patent or patent application in such country but shall not relieve COMPANY from
responsibility to pay PATENT COSTS for such patent or patent application incurred prior to the expiration of the sixty (60) day notice period. Such U.S. or foreign patent application or patent shall thereupon cease to be a PATENT RIGHT
hereunder, COMPANY shall have no further rights therein and HOSPITAL shall be free to license its rights to that particular U.S. or foreign patent application or patent to any other party on any terms. 

7. INFRINGEMENT 
 7.1
HOSPITAL Right to Prosecute. HOSPITAL will protect its PATENT RIGHTS from infringement and prosecute infringers when, in its sole judgment, such action may be reasonably necessary, proper and justified. If COMPANY shall have supplied HOSPITAL
with written evidence demonstrating to HOSPITAL’s reasonable satisfaction prima facie infringement of a claim of a PATENT RIGHT by a third party which poses a material threat to COMPANY’s rights under this AGREEMENT, COMPANY may by notice
request HOSPITAL to take steps to protect the PATENT RIGHT. HOSPITAL shall notify COMPANY within forty five (45) days of the receipt of such notice whether HOSPITAL intends to prosecute the alleged infringement. If HOSPITAL notifies COMPANY
that it intends to so prosecute, HOSPITAL shall, within forty five (45) days of its notice to COMPANY either (i) cause such infringement to terminate, or (ii) initiate legal proceedings against the infringer. 

7.2 COMPANY Right to Prosecute. In the event HOSPITAL notifies COMPANY that HOSPITAL does not intend to prosecute said infringement, or in the
event HOSPITAL does not notify COMPANY within forty-five (45) days whether it intends to prosecute the alleged infringement, or in the event HOSPITAL does not within ninety (90) days of notice by COMPANY either (i) cause such
infringement to terminate or (ii) initiate legal proceedings against the infringer, then in any such event, COMPANY may, upon notice to HOSPITAL, initiate legal proceedings against the infringer at COMPANY’s expense. Before commencing

  
 Frazier-MGH License
Agreement, Execution Version 
 20 
  

 
such action, COMPANY and, as applicable, any AFFILIATE, shall consult with HOSPITAL and shall give careful consideration to the views of HOSPITAL regarding the advisability of the proposed action
and its potential effects on the public interest. COMPANY shall indemnify and hold HOSPITAL harmless from any costs, expenses or liability that HOSPITAL incurs in connection with such action, regardless of whether HOSPITAL is a party-plaintiff,
except for the expense of any independent counsel retained by HOSPITAL in accordance with Section 7.5 below. 
 7.3 Assignment of PATENT
RIGHT. If COMPANY elects to commence an action as described in Section 7.2 above, and in the reasonable opinion of COMPANY’s counsel, HOSPITAL is legally required to be named as a party to such action for standing or other purposes,
HOSPITAL shall have, in its sole discretion, the option to either permit such action to be brought in its name and to be joined as a party-plaintiff, or to assign to COMPANY all of HOSPITAL’s right, title and interest in and to the PATENT RIGHT
which is the subject of such action (subject to all of HOSPITAL’s obligations to the government under law and any other rights that others may have in such PATENT RIGHT). If HOSPITAL elects to permit COMPANY to commence such action to be
brought in its name and to be joined as a party-plaintiff, HOSPITAL shall notify COMPANY of its election within thirty (30) days of notice from COMPANY of an action, or such shorter period as may be necessary to meet any deadlines for
submitting or filing a response. If HOSPITAL at any time elects to assign its PATENT RIGHTS to COMPANY, such action by COMPANY shall thereafter be brought or continued without HOSPITAL as a party, if HOSPITAL is no longer an indispensable party;
provided, however, that COMPANY shall continue to meet all of its obligations under this AGREEMENT, and COMPANY and HOSPITAL shall have the right to effectuate all the provisions of this AGREEMENT, including but not limited the provisions of
Section 10 hereunder, as if the assigned PATENT RIGHT were still licensed to COMPANY. 
 7.4 Settlement. Neither COMPANY nor
HOSPITAL shall enter into any settlement, consent judgment or other voluntary final disposition of any infringement action involving PATENT RIGHTS in the LICENSE FIELD without the prior written consent of the other PARTY. 

7.5 Cooperation. Each PARTY agrees to cooperate reasonably in any action under this Section 7 which is controlled by the other PARTY,
provided that the controlling party reimburses the cooperating party for any costs and expenses incurred by the cooperating party in connection with providing such assistance, except for the expense of any independent counsel retained by the
cooperating party in accordance with this Section 7.5. Such controlling party shall keep the cooperating party informed of the progress of such proceedings and shall make its counsel available to the cooperating party. The cooperating party
shall also be entitled to independent counsel in such proceedings but at its own expense, said expense to be offset against any damages received by the PARTY bringing suit in accordance with Section 7.6. 

7.6 Recovery. Any award paid by third parties as the result of such proceedings (whether by way of settlement or otherwise) shall first be applied
to reimbursement of the unreimbursed legal fees and expenses incurred by the controlling party, then reimbursement of such expenses of the cooperating party, and then the remainder shall be divided between the PARTIES as follows: 

 

	 	(a)    (i)    	if the amount is based on lost profits, COMPANY shall receive an amount equal to the damages COMPANY has suffered as a result of the infringement less the amount of any
royalties and other payments that would have been due HOSPITAL on TRANSFERS of PRODUCT and PROCESSES lost by COMPANY and any other lost opportunities, as a result of the infringement; and 

  
 Frazier-MGH License
Agreement, Execution Version 
 21 
  

	 	(ii)    	HOSPITAL shall receive an amount equal to the royalties and other payments it would have received if such TRANSFERS had been made and such other opportunities captured
by COMPANY; and 

  

	 	(b)	The remainder of any awards other than those based on lost profits shall be shared equally by the PARTIES. 

8. INDEMNIFICATION AND INSURANCE 
 8.1 Indemnification. 
  

	 	(a)	COMPANY shall indemnify, defend and hold harmless HOSPITAL and its AFFILIATES and their respective trustees, directors, officers, medical and professional staff,
employees, and agents and their respective successors, heirs and assigns (the “INDEMNITEES”), against any liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) incurred by or imposed upon
the INDEMNITEES or any one of them in connection with any claims, suits, actions, demands or judgments arising out of any theory of product liability (including, but not limited to, actions in the form of tort, warranty, or strict liability)
concerning any PRODUCT or PROCESS used or sold pursuant to any right or license granted under this AGREEMENT, provided, however, that the above indemnification shall not apply to any liability, damage, loss or expense to the extent that it is
directly attributable to the negligence, gross negligence, reckless misconduct or intentional misconduct of any INDEMNITEE. 

  

	 	(b)	 As a condition of COMPANY’s indemnity obligation in Section 8.1(a) above, HOSPITAL shall promptly notify COMPANY of any actual claim or
action with respect to the subject matter of the indemnity in this AGREEMENT, provided however that a delay in giving such notice shall relieve COMPANY of its indemnity obligation only to the extent that such delay actually increases COMPANY’s
ultimate indemnity obligation; and hereby gives COMPANY authority to control the defense of any third party claim or action and the defense and settlement thereof with counsel of its own choice that are reasonably acceptable to the HOSPITAL. COMPANY
shall, at its own expense, defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. Any INDEMNITEE shall have
the right to retain its own 

  
 Frazier-MGH License
Agreement, Execution Version 
 22 
  

	 	 
counsel, at its own expense, if representation of such INDEMNITEE by counsel retained by COMPANY would be inappropriate because of actual or potential differences in the interests of such
INDEMNITEE and any other party represented by such counsel. COMPANY agrees to keep HOSPITAL informed of the progress in the defense and disposition of such claim and to consult with HOSPITAL prior to any proposed settlement.

  

	 	(c)	This section 8.1 shall survive expiration of termination of this AGREEMENT. 

 8.2 Insurance. 
  

	 	(a)	Beginning at such time as any such PRODUCT or PROCESS is being commercially distributed, sold, leased or otherwise transferred, or performed or used (other than for the
purpose of obtaining regulatory approvals), by COMPANY, an AFFILIATE, or SUBLICENSEE, COMPANY shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $2,000,000 per incident and
$2,000,000 annual aggregate and naming the INDEMNITEES as additional insureds. Such commercial general liability insurance shall provide (i) product liability coverage and (ii) broad form contractual liability coverage for COMPANY’s
indemnification under Section 8.1 of this AGREEMENT. If COMPANY elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $250,000 annual aggregate) such self-insurance program
must be acceptable to the HOSPITAL and the Risk Management Foundation. The minimum amounts of insurance coverage required under this Section 8.2 shall not be construed to create a limit of COMPANY’s liability with respect to its
indemnification under Section 8.1 of this AGREEMENT. 

  

	 	(b)	COMPANY shall provide HOSPITAL with written evidence of such insurance upon request of HOSPITAL. COMPANY shall provide HOSPITAL with written notice at least fifteen
(15) days prior to the cancellation, non-renewal or material change in such insurance; if COMPANY does not obtain replacement insurance providing comparable coverage prior to the expiration of such fifteen (15) day period, HOSPITAL shall
have the right to terminate this AGREEMENT effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 

  

	 	(c)	COMPANY shall maintain such commercial general liability insurance beyond the expiration or termination of this AGREEMENT during (i) the period that any such
product, process, or service is being commercially distributed, sold, leased or otherwise transferred, or performed or used (other than for the purpose of obtaining regulatory approvals), by COMPANY or by a licensee, affiliate or agent of COMPANY
and (ii) a reasonable period after the period referred to in (c) (i) above which in no event shall be less than fifteen (15) years. 

  

	 	(d)	This section 8.2 shall survive expiration of termination of this AGREEMENT. 

  
 Frazier-MGH License
Agreement, Execution Version 
 23 
  

 9. WARRANTIES AND DISCLAIMER 
 9.1 Limited Warranties and Representations. 
  

	 	(a)	To the best knowledge of HOSPITAL’s Office of Corporate Sponsored Research and Licensing, HOSPITAL is the owner by assignment from INVESTIGATORS of the PATENT
RIGHTS and has the right, power, and authority to enter into this agreement and license the PATENT RIGHTS to COMPANY hereunder. 

  

	 	(b)	To the best knowledge of HOSPITAL’s Office of Corporate Sponsored Research and Licensing, the execution and performance of this AGREEMENT does not conflict with,
cause a default under, or violate any existing contractual obligation that may be owed by HOSPITAL to any third person. 

  

	 	(c)	To the best knowledge of HOSPITAL’s Office of Corporate Sponsored Research and Licensing, HOSPITAL has not granted licenses or other rights to practice the PATENT
RIGHTS to any other entity. 

 9.2 No Warranties. EXCEPT AS MAY BE EXPRESSLY SET FORTH HEREIN, HOSPITAL MAKES NO
REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE PATENT RIGHTS AND THE RIGHTS GRANTED HEREUNDER, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, VALIDITY OF PATENT RIGHTS
CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, AND HEREBY DISCLAIMS THE SAME. SPECIFICALLY, AND NOT TO LIMIT THE FOREGOING, HOSPITAL MAKES NO WARRANTY OR REPRESENTATION (i) REGARDING
THE VALIDITY OR SCOPE OF ANY OF THE CLAIM(S), WHETHER ISSUED OR PENDING, OF ANY OF THE PATENT RIGHTS, AND (ii) THAT THE EXPLOITATION OF THE PATENT RIGHTS OR ANY PRODUCT WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF
HOSPITAL OR OF ANY THIRD PARTY. 
 9.3 Disclaimer. IN NO EVENT SHALL EITHER HOSPITAL OR COMPANY OR ANY OF THEIR AFFILIATES OR THEIR
RESPECTIVE TRUSTEES, DIRECTORS, OFFICERS, MEDICAL AND PROFESSIONAL STAFF, EMPLOYEES AND AGENTS BE LIABLE FOR SPECIAL, INCIDENTAL, TORT OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING WITHOUT LIMITATION ECONOMIC DAMAGES OR INJURY TO PROPERTY OR LOST
PROFITS, REGARDLESS OF WHETHER HOSPITAL OR COMPANY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING. Notwithstanding the foregoing, nothing contained in this Section 9.3 shall be
deemed to limit COMPANY’s obligation to indemnify HOSPITAL pursuant to Section 8.1 above for any amounts HOSPITAL is obligated to pay to third parties. 

  
 Frazier-MGH License
Agreement, Execution Version 
 24 
  

 10. TERM AND TERMINATION 
 10.1 Term. The term of this AGREEMENT shall commence on the EFFECTIVE DATE and shall remain in effect until the later of (a) the date on which all issued patents and filed patent applications
within the PATENT RIGHTS have expired or been abandoned, and (b) one (1) year after the last COMMERCIAL SALE for which a royalty is due under Section 4.5(a)(i), unless this AGREEMENT is terminated earlier in accordance with the
provisions of this Section 10. 
 10.2 Termination for Failure to Pay. If COMPANY fails to make any payment due hereunder, HOSPITAL
shall have the right to terminate this AGREEMENT upon ten (10) business days written notice, unless COMPANY makes such payments plus any interest due, as set forth in Section 4.9, within said ten (10) day notice period. If payments
are not made, HOSPITAL may immediately terminate this AGREEMENT at the end of said ten (10) day period. COMPANY shall be entitled to only one such cure period in a calendar year; for a second failure to make payment on time within a calendar
year, HOSPITAL shall have the right to terminate this AGREEMENT immediately upon written notice. 
 10.3 Termination for Insurance and
Insolvency. HOSPITAL shall terminate this AGREEMENT immediately upon written notice with no further notice obligation or opportunity to cure if COMPANY fails to maintain the insurance required by Section 8.2 or if COMPANY shall become
insolvent, shall make an assignment for the benefit of creditors, or shall have a petition in bankruptcy filed for or against it. 
 10.4
Termination for Non-Financial Default. If COMPANY, its AFFILIATES or SUBLICENSEES shall materially breach its obligations under this AGREEMENT, including but not limited to its obligations under Section 3.1(b)(i) or 3.1(b)(ii), and if
such breach has not been cured within sixty (60) days (or ninety (90) days with respect to breaches of the obligations in Section 3) after notice by HOSPITAL in writing of such breach, HOSPITAL may immediately terminate any licenses
granted hereunder with respect to the country or countries in which such default has occurred at the end of said cure period. HOSPITAL shall also have the right to terminate such licenses immediately upon written notice, in the event of repeated
defaults within one calendar year, even if cured within such sixty (60) or ninety (90) day periods, as the case may be. 
 10.5
Termination by Company. COMPANY shall have the right to terminate this AGREEMENT by giving ninety (90) days advance written notice to HOSPITAL and upon such termination shall immediately cease all use and TRANSFER of PRODUCTS and
PROCESSES. 
 10.6 Effect of Termination on Sublicenses. Any sublicenses granted by COMPANY under this AGREEMENT shall provide for
termination, or assignment to HOSPITAL of COMPANY’s interest therein, consistent with the terms and conditions set forth in this Section 10.6, upon termination of this AGREEMENT or upon termination of any license hereunder under which such
sublicense has been granted. In the event of termination of this AGREEMENT or any of the licenses hereunder, if a sublicense agreement is consistent with this AGREEMENT, HOSPITAL shall, within thirty (30) days after such termination, notify
each SUBLICENSEE of HOSPITAL’s intent to accept direct assignment of such sublicense agreement and accept such 

  
 Frazier-MGH License
Agreement, Execution Version 
 25 
  

 
assignment. In the event of termination of this AGREEMENT or any of the licenses hereunder, if HOSPITAL determines that a sublicense agreement is not consistent with this AGREEMENT, HOSPITAL
shall terminate such sublicense agreement and HOSPITAL shall grant a direct license to each SUBLICENSEE effective as of the date of termination of this AGREEMENT provided that (i) SUBLICENSEE is not in default under its sublicense agreement, at
the time of the termination of this AGREEMENT, and (ii) within thirty (30) days after the termination of this AGREEMENT, HOSPITAL notifies the SUBLICENSEE in writing that it has reasonably determined that the sublicense agreement is not
consistent with this AGREEMENT. HOSPITAL shall negotiate with SUBLICENSEE in good faith the direct license from HOSPITAL to SUBLICENSEE under the PATENT RIGHTS and TECHNOLOGICAL INFORMATION (or the subset of the PATENT RIGHTS and TECHNOLOGICAL
INFORMATION that was sublicensed to the SUBLICENSEE) in the sublicensed field, and such direct license shall otherwise be on the terms and conditions of the sublicense agreement between COMPANY and SUBLICENSEE to the extent that such terms are
consistent with this AGREEMENT, provided however that if the economic terms in such sublicense agreement are less than the economic terms in this AGREEMENT, HOSPITAL shall not be obligated to grant a direct license unless the SUBLICENSEE agrees that
the economic terms in the direct license agreement between the HOSPITAL and SUBLICENSEE shall be amended so that such terms are no less than what HOSPITAL would have received from COMPANY as a result of the sublicense from COMPANY to SUBLICENSEE and
SUBLICENSEE’s performance thereunder had this AGREEMENT between HOSPITAL and COMPANY survived. 
 10.7 Effects of Termination of
AGREEMENT. Subject to Section 10.6 above, upon termination of this AGREEMENT or any of the licenses hereunder for any reason, final reports in accordance with Section 5 shall be submitted to HOSPITAL and all royalties and other
payments, including without limitation any unreimbursed PATENT COSTS, accrued or due to HOSPITAL as of the termination date shall become immediately payable. COMPANY shall cease, and shall cause its AFFILIATES and SUBLICENSEES to cease under any
sublicense granted by COMPANY, all TRANSFERS and uses of PRODUCTS and PROCESSES upon such termination. The termination or expiration of this AGREEMENT or any licenses granted hereunder shall not relieve COMPANY, its AFFILIATES or SUBLICENSEES of
obligations arising before such termination or expiration. 
 11. COMPLIANCE WITH LAW 

11.1 Compliance. COMPANY shall have the sole obligation for compliance with, and shall ensure that any AFFILIATES and SUBLICENSEES comply with,
all government statutes and regulations that relate to PRODUCTS, including, but not limited to, FDA statutes and regulations and the Export Administration Act of 1997, as amended, and the regulations promulgated thereunder, and any applicable
similar laws and regulations of any other country in the LICENSE TERRITORY. 
 11.2 Patent Numbers. COMPANY shall cause all PRODUCTS sold
in the United States to be marked with all applicable U.S. Patent Numbers, to the full extent required by United States law. COMPANY shall similarly cause all PRODUCTS shipped to or sold in any other country to be marked in such a manner as to
conform with the patent laws and practices of such country. 

  
 Frazier-MGH License
Agreement, Execution Version 
 26 

 12. MISCELLANEOUS 
 12.1 Entire Agreement. This AGREEMENT constitutes the entire understanding between the PARTIES with respect to the subject matter hereof. 
 12.2 Notices. Any written notices, reports, waivers, correspondences or other communications required under or pertaining to this AGREEMENT, and including all payments required hereunder, shall be
given by prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other PARTY, which for HOSPITAL shall be as follows: 

Director, Corporate Sponsored Research and Licensing 
 Massachusetts General Hospital 
 Building 149, 13th Street, Suite 5036 

Charlestown, MA 02129 
 Notices
and payments shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by legibly dated U.S. Postal Service postmark or dated receipt from a commercial
carrier. 
 12.3 Amendment; Waiver. This AGREEMENT may be amended and any of its terms or conditions may be waived only by a written
instrument executed by an authorized signatory of the PARTIES or, in the case of a waiver, by the PARTY waiving compliance. The failure of either PARTY at any time or times to require performance of any provision hereof shall in no manner affect its
rights at a later time to enforce the same. No waiver by either PARTY of any condition or term shall be deemed as a further or continuing waiver of such condition or term or of any other condition or term. 

12.4 Binding Effect. This AGREEMENT shall be binding upon and inure to the benefit of and be enforceable by the PARTIES hereto and their
respective permitted successors and assigns. 
 12.5 Assignment. Except as set forth in this Section 12.5, COMPANY shall not assign
any of its rights or obligations under this AGREEMENT without the prior written consent of HOSPITAL. Provided that COMPANY has fulfilled its diligence obligations as set forth in Section 3, no such consent will be required, however, to assign
this AGREEMENT to a successor of the COMPANY’s business to which this AGREEMENT pertains or to a purchaser of substantially all of the COMPANY’s assets related to this AGREEMENT, so long as such successor or purchaser shall agree in
writing to be bound by the terms and conditions hereof prior to such assignment. COMPANY shall notify HOSPITAL in writing of any such assignment and provide a copy of all assignment documents and related agreements to HOSPITAL within thirty
(30) days of such assignment. Failure of an assignee to agree to be bound by the terms hereof or failure of COMPANY to notify hospital and provide copies of assignment documentation shall be grounds for termination of this AGREEMENT for
default. 

  
 Frazier-MGH License
Agreement, Execution Version 
 27 

 12.6 Force Majeure. Neither PARTY shall be responsible for delays resulting from causes beyond the
reasonable control of such PARTY, including without limitation fire, explosion, flood, war, sabotage, strike or riot, provided that the nonperforming PARTY uses commercially reasonable efforts to avoid or remove such causes of nonperformance and
continues performance under this AGREEMENT with reasonable dispatch whenever such causes are removed. 
 12.7 Use of Name. Neither PARTY
shall use the name of the other PARTY or of any trustee, director, officer, staff member, employee, student or agent of the other PARTY or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document
employed to obtain funds or financing without the prior written approval of the PARTY or individual whose name is to be used. For HOSPITAL, such approval shall be obtained from HOSPITAL’s Chief Public Affairs Officer. 

12.8 Governing Law. This AGREEMENT shall be governed by and construed and interpreted in accordance with the laws of the Commonwealth of
Massachusetts, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted. Each PARTY agrees to submit to the exclusive jurisdiction of the
Superior Court for Suffolk County, Massachusetts, and the United States District Court for the District of Massachusetts with respect to any claim, suit or action in law or equity arising in any way out of this AGREEMENT or the subject matter
hereof. 
 12.9 Hospital Policies. COMPANY acknowledges that HOSPITAL’s employees and medical and professional staff members and the
employees and staff members of HOSPITAL’s AFFILIATES are subject to the applicable policies of HOSPITAL and such AFFILIATES, including, without limitation, policies regarding conflicts of interest, intellectual property and other matters.
COMPANY shall provide HOSPITAL with any agreement it proposes to enter into with any employee or staff member of HOSPITAL or any of HOSPITAL’s AFFILIATES for HOSPITAL’s prior review and shall not enter into any oral or written agreement
with such employee or staff member which conflicts with any such policy. HOSPITAL shall provide COMPANY, at COMPANY’s request, with copies of any such policies applicable to any such employee or staff member. 

12.10 Severability. If any provision(s) of this AGREEMENT are or become invalid, are ruled illegal by any court of competent jurisdiction or are
deemed unenforceable under then current applicable law from time to time in effect during the term hereof, it is the intention of the PARTIES that the remainder of this agreement shall not be effected thereby. It is further the intention of the
PARTIES that in lieu of each such provision which is invalid, illegal or unenforceable, there be substituted or added as part of this AGREEMENT a provision which shall be as similar as possible in economic and business objectives as intended by the
PARTIES to such invalid, illegal or enforceable provision, but shall be valid, legal and enforceable. 
 12.11 Survival. In addition to
any specific survival references in this AGREEMENT, Sections 1, 2.4, 5.5, 5.6, 8.1, 8.2, 9.2, 9.3, 10.6, 10.7, 11.1, 12.2, 12.7, 12.8, 12.9, 12.10, 12.11, 12.12 and 12.13 shall survive termination or expiration of this AGREEMENT. 

  
 Frazier-MGH License
Agreement, Execution Version 
 28 

 12.12 Interpretation. The PARTIES hereto are sophisticated, have had the opportunity to consult legal
counsel with respect to this transaction and hereby waive any presumptions of any statutory or common law rule relating to the interpretation of contracts against the drafter. 
 12.13 Headings. All headings are for convenience only and shall not affect the meaning of any provision of this AGREEMENT. 
 12.14 Amendment and Restatement of Original Agreement. The ORIGINAL AGREEMENT shall be amended in its entirety and restated herein upon the execution and delivery of this AGREEMENT by the PARTIES.
Upon such execution and delivery, all provisions of the ORIGINAL AGREEMENT are hereby waived, released and superseded in their entirety and shall have no further force or effect. Notwithstanding the foregoing, any payment made by COMPANY pursuant to
the ORIGINAL AGREEMENT shall be credited against any payment due pursuant to this AGREEMENT, whether or not such payment was made prior to the date of this AGREEMENT. 
 [Remainder of page intentionally left blank.] 

  
 Frazier-MGH License
Agreement, Execution Version 
 29 

 IN WITNESS WHEREOF, the PARTIES have caused this AGREEMENT to be executed by their duly
authorized representatives as of the date first written above. 
  

									
	COMPANY	 		 	HOSPITAL
					
	BY:	 	 /s/ John Howe
	 		 	BY:	 	 /s/ Irene Erenburg

	Name:	 		 		 	Name:	 	
					
	TITLE:	 	 CFO
	 		 	TITLE:	 	 Director, Strategic Transactions Research Ventures & Licensing

					
	DATE:	 	 Sept. 23, 2011
	 		 	DATE:	 	 9/22/11

  
 Frazier-MGH License
Agreement, Execution Version 
 30 

 Appendix A 
 PATENT RIGHTS 
 1. US Utility Patent Application, Serial
No. 10/391,221, filed on March 17th, 2003,
claiming priority from US Provisional Application, Serial No. 60/365,662, filed on March 15th, 2003. 
 2. US Utility Patent Application, Serial No. 11/016,196, filed
on December 17th, 2003, a continuation in part of US
Utility Patent Application, Serial No 10/391,221. 
 3. PCT Patent Application, Serial No. US03/08014, filed on March 17, 2003. 

4. Australia: Patent Application No. 2003220311, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

5. Brazil: Patent Application No. 0308642.9, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

6. Canada: Patent Application No. 2,478,887, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

7. China: Patent Application No. 03810938.7, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

8. Israel: Patent Application No. 164115, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

9. Japan: Patent Application No. 2003-576590, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

10. Mexico: Patent Application No. 2004-008992, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

11. EPO: Patent Application No. 03711609.7, claiming priority from PCT Patent Application No. PCT/US03/08014, filed on
March 17th, 2003. 

  
 Frazier-MGH License
Agreement, Execution Version 
 31 

 Appendix B 
 SALES REPORTS 

  
 Frazier-MGH License
Agreement, Execution Version 
 32Distribution Agreement

 Exhibit 10.49 
 [***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with respect to the omitted portions. 

DISTRIBUTION AGREEMENT 
 between 
 ZELTIQ AESTHETICS, INC. 

And 

ADVANCE Medical, Inc 
  

					
	ZELTIQ AESTHETICS, INC.	  		 	
	 Address:
	  		 	
	 4698 Willow Road
	  	 Attention:
	 	 John Howe

	 Pleasanton, CA 94588
	  		 	 Chief Financial Officer

			
	ADVANCE MEDICAL, INC.	  		 	
	 Address:
	  		 	
	 530 Fifth Avenue, 22nd Floor,
	  	 Attention:
	 	 Fred Aslan

	 New York, NY 10036
	  		 	   Chief Executive Officer

		
	EFFECTIVE DATE:	  	 March 18, 2011
  

  

  
 ZELTIQ
CONFIDENTIAL 
  

 DISTRIBUTION AGREEMENT 

This DISTRIBUTION AGREEMENT is hereby made and entered into as of the Effective Date (as
specified on the cover page of this Agreement) by and between Zeltiq Aesthetics, Inc., a company incorporated under the laws of Delaware with an office located at 4698 Willow Road, Pleasanton, CA, 94588, USA (“Zeltiq”) and ADVANCE
Medical, Inc , a company incorporated under the laws of Delaware with an office located at 530 Fifth Avenue, 22nd Floor, New York, NY 10036 (“Distributor”). 

WHEREAS, Zeltiq has developed and manufactures, markets and sells medical devices and related items.

 WHEREAS, Distributor is experienced in the importation, distribution, marketing, sale and
support of such equipment and desires to promote and distribute certain Zeltiq products in the Territory, as defined below. 
 NOW, THEREFORE, in consideration of the mutual covenants and conditions herein contained, and intending to be legally bound by this Agreement, the parties agree as follows:

  

	1.	SCOPE OF THE AGREEMENT 

 (a) Appointment. Subject to the terms and conditions of this Agreement, including the requirements set forth in Section 2, Zeltiq hereby appoints Distributor as the authorized distributor of
the Zeltiq products (“Products”) listed in Exhibit A, Section 2 and in the territory set forth on Exhibit A, Section 1 (“Territory”) and Distributor accepts such appointment. Furthermore, Distributor may have the
opportunity to be appointed an exclusive territory that shall be defined in Exhibit A, Section 1. The term “exclusive” as used herein means that as long as Distributor is complying with this Agreement Zeltiq shall not appoint another
third party distributor to sell Products in the Territory. 
 (b) Sole Supplier. Distributor shall not
obtain the Products for resale from any person or entity other than Zeltiq. Notwithstanding the longer duration of the Agreement, this exclusive purchase obligation applies for a maximum period of five (5) years from the Effective Date and is
contingent upon the continued duration of the Agreement for such period of time. Distributor may not sell the Products to customers in another territory where Zeltiq has exclusively reserved such territory for itself or another distributor,
Distributor shall be prevented from directly or indirectly (including through its affiliates), actively searching and filling orders for any of the Products in that other territory. However, Distributor shall not be prevented from accepting and
filling unsolicited orders for the Products from a customer located outside the Territory. 
 (c) Authorized
Supplies. Distributor shall sell, offer for sale and promote only the supplies, spare parts, Procedure Cards (as defined in Section 5(a)) and other peripheral equipment listed on Exhibit A, Section 2 (collectively “Supplies”)
for use in conjunction with the Control Unit and Applicator (as such terms are defined below). Distributor shall not sell, offer for sale or promote the use of expired or reprocessed Procedure Cards . For clarity, Supplies are “Products”
for purposes of this Agreement. 
 (d) Products. Zeltiq reserves the right to discontinue or modify the
Products, modify the Product specifications, or replace the Products with other Zeltiq or third party products in its sole discretion, provided that, except as required by law, any such discontinuations, modifications, or replacements will not apply
to Products that are subject to an outstanding purchase order accepted by Zeltiq pursuant to Section 4. 

  
 2 

ZELTIQ CONFIDENTIAL 

 (e) Competitive Products. During the Term, the Distributor shall not
promote or sell, directly or indirectly, any products or treatments manufactured or offered for sale by another person or entity, which product or treatment serves the purpose of localized fat removal or body sculpting for esthetic purposes [by
freezing] (the “Field”) (each, a “Competing Product”). Distributor warrants that it does not promote or sell, directly or indirectly, any Competing Products as of the Effective Date. During the Term (as defined below),
Distributor shall disclose to Zeltiq any new products or treatments for use in the aesthetic improvement field that Distributor intends to promote or sell, as well as the manufacturer of such products or treatments, prior to promoting or selling
such products or treatments and Distributor will have the right to promote and sell such products as long as they are not reasonably deemed by Zeltiq to be Competing Products. 

(f) Certain Entities. Zeltiq may prohibit Distributor from providing Products to any entity or person that it
reasonably believes is using the Products in violation of: (i) the terms of this Agreement or any Customer Agreement (as defined below), or (ii) any law, regulation, policy, guideline, order, or similar authority issued by a federal, state
or local government or any agency, board or commission thereof. 
 (g) Independent Contractors. The
relationship of Zeltiq and Distributor established by this Agreement is that of independent contractors and nothing contained herein shall be construed to: (i) give either party the power to direct and control the day-to-day activities of the
other, (ii) constitute the parties as partners, joint ventures, co-owners or otherwise as participants in a joint or common undertaking, or (iii) allow Distributor to create or assume any obligation on behalf of Zeltiq. All financial
obligations associated with Distributor’s business and its performance under this Agreement are the sole responsibility of Distributor. All sales and other agreements between Distributor and its Customers are Distributor’s exclusive
responsibility and shall have no effect on Distributor’s or Zeltiq’s obligations under this Agreement. 
 (h) Subdistributors. Notwithstanding anything to the contrary herein, Distributor shall have the ability to appoint and use (i) its parent and any of its subsidiaries and affiliates
(collectively “Affiliates”) and (ii) TransUniversal (“TU”) (through its affiliate, United Medical Ltda. (“UM”)) to market, sell and distribute the Products. Distributor shall ensure that each of the
foregoing entities are bound to the terms and conditions of this Agreement as if original signatories hereto, exception made to the term and any other specific provisions that may be described in the relevant subdistribution agreement. Distributor
shall not appoint or use any additional third parties to market, sell or distribute the Products unless such subdistributors, and Distributor’s written agreement authorizing such subdistributor to market, sell or distribute Products, has been
expressly approved by Zeltiq in writing. Distributor shall be liable for, and shall indemnify Zeltiq against, any damages or losses caused to Zeltiq by any subdistributors appointed by Distributor pursuant to this Section 1(h). Furthermore,
Distributor warrants that the authorized subdistributors may only market, sell and distribute the Products if they have the proper permits before the relevant Brazilian regulatory authorities to do so, including, but not limited to, the Brazilian
National Health Surveillance Agency (“ANVISA”). Distributor agrees that its agreement with TU and UM shall be in the form previously provided to Zeltiq, and Distributor agrees that it will not amend or remove any provisions from
such agreement that affect Zeltiq’s rights without Zeltiq’s prior written consent. Distributor agrees that Zeltiq may, in its sole discretion, at any time following the date that is 180 days after the date of this Agreement, revoke the
ability of Distributor to appoint and use any subdistributor to market, sell and distribute the Products. 
  

	2.	RESPONSIBILITIES OF DISTRIBUTOR 

 (a) Marketing and Promotion Generally. Distributor shall use its commercially reasonably efforts to promote and sell the Products in the Territory, and shall at its cost and expense:
(i) devote part of its own work force, in a sufficient number of specialized, trained, and qualified personnel 

  
 3 

ZELTIQ CONFIDENTIAL 

 
to promote and sell the Products in the Territory; (ii) maintain, within its existing structure, a dedicated professional sales and service organization as necessary to install the Product
at Customer locations and to provide training and Customer service for the Product in the Territory; and (iii) otherwise operate its business in a professional and ethical manner, in each case in accordance with this Agreement. For avoidance of
doubts, the Distributor warrants that (i) no relevant operational infrastructure investment (e.g. office, sales personnel) is necessary for the performance of this Agreement and (ii) in the same sense, the authorized subdistributors have
the necessary structure to perform all obligations in connection with the market, sale and distribution of the Products. 
 (b) Marketing Plan. Distributor shall provide a twelve (12) month sales and marketing plan (“Annual Marketing Plan”) for Zeltiq’s review and approval within sixty
(60) days of the Effective Date of this Agreement, which plan shall (i) list sales goals for the following twelve (12) month period for each Product, (ii) specify Distributor’s planned media activities in support of each
Product, (iii) identify key opinion leaders on which sales and marketing efforts will be focused, and (iv) establish an audit plan for Customer accounts to assess (A) procedure expectation management, (B) patient selection, and
(C) Product usage. Distributor shall update the Annual Marketing Plan and provide such updated plan to Zeltiq at least sixty (60) days prior to each anniversary of the date the first Annual Marketing Plan was approved by Zeltiq. Upon
Zeltiq’s approval, Distributor shall implement the Annual Marketing Plan. 
 (c) Monthly Forecasts;
Sales and Marketing Reports. During the first week of each calendar month, Distributor will provide to Zeltiq a Product purchase forecast and a sales and marketing report in the form and format set forth on Exhibit F (“Monthly Forecast,
Sales and Marketing Report”). Each Forecast, Sales and Marketing Report shall contain a forecast that specifies the number of Products Distributor intends to purchase during the ninety (90) day period beginning on the date of the report
(“Forecast”). 
 (d) Quarterly System Quota. Upon execution of this Agreement Distributor will
purchase an “Initial Order” of Products as set forth on Exhibit A, Section 3. Each calendar quarter during the Term, Distributor shall purchase a minimum quantity of Products set forth on Exhibit A, Section 3 (the “Quarterly
System Quota”). The Quarterly System Quotas for the first calendar year are set forth on Exhibit A, Section 3. Zeltiq and Distributor shall establish a Quarterly System Quota for the four quarters of each calendar year within sixty
(60) days prior to the start of such calendar year. If Distributor fails to meet the Quarterly System Quota for any calendar quarter, Zeltiq may, upon written notice to Distributor, at Zeltiq’s option either convert Distributor’s
exclusive rights in the Territory to non exclusive rights for the remainder of the Term or terminate this Agreement in accordance with Section 6 (b). 
 (e) General Performance Standards. Distributor agrees that the continued maintenance of an image of excellence and ethical marketing of the Products is essential to the continued success of both
parties. Accordingly, Distributor: 
 (1) shall not engage in deceptive, misleading, or unethical practices that
are or might be detrimental to Zeltiq, the Products, or the public, including any such practices directed at Competing Products; 
 (2) shall make no false, misleading or deceptive statements or representations, either orally or in any written materials, with regard to Zeltiq, Distributor or the Products; 

(3) shall make no representations, warranties, or guarantees to Customers or to the trade with respect to the
specifications, indications, capabilities, or features of the Product that are inconsistent with the literature provided to Distributor by Zeltiq for marketing purposes; and 

(4) shall not promote the Products other than for use with their labeled indications. 

  
 4 

ZELTIQ CONFIDENTIAL 

 (f) Legal Compliance. Distributor shall comply at its expense with
all laws governing the distribution, promotion, marketing, training and sale of the Products in the Territory. Without limiting the foregoing, Distributor: 
 (1) shall, except for Zeltiq’s obligation with respect to maintenance of quality systems in accordance with Section 3(c), obtain, directly or through its Affiliates or subdistributors, all
governmental authorizations, licenses, filings, approvals and similar requirements, such as medical device approvals, export/import licenses and foreign exchange permits, necessary or advisable to import, distribute and sell the Products in the
Territory (collectively, “Approvals”). To the fullest extent allowed under applicable law, all Approvals shall be obtained in the name of Zeltiq alone. Distributor shall provide copies of all Approvals to Zeltiq promptly after they are
obtained. Distributor represents and warrants that all Approvals Distributor (or its Affiliates or subdistributors) has not obtained prior to the Effective Date shall be obtained by the Distributor (or its Affiliates or subdistributors) prior to the
importation, distribution or sale of Products in the Territory. Nothing in this Agreement shall limit Zeltiq’s right in its sole discretion to obtain for itself any Approval. Zeltiq shall have the option to acquire any Approval obtained by
Distributor (or its Affiliates or subdistributors), or any application for such an Approval, including all related documentation and any documents required to facilitate and execute the transfer of such Approval or application to Zeltiq or its
nominee, by (i) providing 90 days prior written notice at any time during the Term or within 90 days after termination of this Agreement, and (ii) paying Distributor an amount for such Approval not to exceed US$5,000 for each country to
which the Approval applies. 
 (2) shall keep Zeltiq informed in writing of regulatory requirements, and any
changes thereto, imposed by the laws of the Territory applicable to the Products and on any and all efforts made by Distributor to comply therewith; 
 (3) shall comply promptly with any recalls of the Product issued by Zeltiq or by any applicable regulatory authorities; 

(4) shall comply with the obligations specified in Exhibit B and shall otherwise accept notifications from Customers or
any physician or user of the Product in the Territory regarding complaints and adverse events with respect to the Products, including: alleged or actual Product malfunctions; alleged or actual injury to patients or operators (even if caused by use
error); alleged or actual counterfeiting; non-routine servicing or installation, e.g., repairs of an unexpected nature, replacement of parts earlier than their normal life expectancy, or identical repairs or replacements of multiple units of a
device are not routine servicing (collectively, “Complaints”). Distributor shall notify Zeltiq of any Complaints within twenty four (24) hours of the Distributor becoming aware of the complaint, meaning that an employee or contractor
of the Distributor has acquired information that suggests a Complaint may have occurred; 
 (5) shall maintain a
detailed tracking system that enables Distributor to track Products by Customer, physician or recipient name and address, part number(s) shipped, serial number(s) shipped, quantity shipped and dates of shipment, and shall provide such information
within twenty four (24) hours upon request by Zeltiq; 
 (6) at the request of Zeltiq, shall forward to
physicians and any other recipients of the Product in the Territory communications or notifications originated by Zeltiq and shall provide written confirmation of having delivered such requested communications or notifications to such recipients
within five (5) days after delivery to Distributor, provided that Zeltiq will be responsible for any additional costs incurred to meet this obligation above and beyond normal post or next day document delivery charges; 

(7) shall designate an employee of Distributor as regulatory liaison to Zeltiq and shall notify Zeltiq of the identity
and contact details of such employee; 

  
 5 

ZELTIQ CONFIDENTIAL 

 (8) shall promptly advise Zeltiq of any laws, rules or regulations in the
Territory that may require Zeltiq to modify a Product otherwise take any action in connection with the Products or this Agreement; 
 (9) shall maintain records as necessary to comply with, and to demonstrate its compliance with, all applicable laws, rules and regulations with respect to the sale of the Products in the Territory; and

 (10) shall comply with the laws of the Territory, the United States and any other applicable jurisdiction
(including the U.S. Foreign Corrupt Practices Act) that address payments to governments or related persons for the purpose of obtaining or retaining business for or with, or directing business to, any person, or otherwise affecting the actions of
any government personnel. 
 (g) Translation of Product Materials. Unless otherwise directed by Zeltiq in
its sole discretion, Distributor: 
 (1) shall, at its expense using language experts reasonably familiar with
aesthetic products and medical device terminology in the Territory for the Products (“Translators”), timely review all technical, labeling, advertising, marketing and training materials and all notices or other materials supplied by or on
behalf of Zeltiq (collectively, “Product Materials”) as previously translated into one or more languages appropriate for the Territory, specially Portuguese. Distributor shall provide written feedback (“Translation Feedback”)
regarding its review of the translated Product Materials to Zeltiq and/or its designate within forty-five (45) days of its receipt of translated Product Materials. Translation Feedback shall contain, at a minimum: (A) suggestions for
corrections to the translated Product Materials consistent with the original English versions so as to maintain their accuracy and so as not to alter their content or meaning, consistent with the idioms and customs of the Territory (collectively or
individually, a “Conforming Translation”), (B) copies of translated Product Materials as so corrected, (C) explanation of suggested corrections, or, in the case no corrections are suggested, (D) confirmation that the
translated Product Materials suffice as Conforming Translations. 
 (2) alternatively, as may be directed by
Zeltiq in its sole discretion, Distributor shall translate, at its expense using Translators, all English versions of Product Materials into one or more languages appropriate for the Territory, specially Portuguese, to produce Conforming
Translations. At least forty-five (45) days prior to distributing Products or using such translations in commerce, Distributor shall provide Zeltiq and/or its designate with copies of all translations for review and approval. Distributor shall
make any changes to the translated Product Materials requested by Zeltiq and/or its designate in connection with a review of such materials. 
 Distributor shall not distribute any translated Product Materials until Zeltiq has finally approved such materials in writing. Distributor hereby assigns all its rights in the translated Product Materials
to Zeltiq and Zeltiq hereby grants Distributor a non-exclusive, non-transferable license during the Term to reproduce and distribute the translated Product Materials solely in connection with the distribution of the Products in accordance with this
Agreement. 
 (h) Customer Support, Training, Certification and Product Service 

(1) Distributor shall have the sole responsibility for (A) obtaining orders for Products from Customers,
(B) installing the Products at Customer locations, (C) providing First-Level Support to Customers, (D) training Customers with respect to the Products sold by Distributor, and (E) handling all other interactions with Customers in
the Territory with respect to the Products. Without limiting Distributor’s other obligations in this subsection (h), Distributor shall at all times maintain a sufficient level of understanding of the Products to enable Distributor to provide
basic technical information to Customers regarding the Products, to effectively sell and service the Products, and to obtain Customer orders and provide assistance to Customers in determining and fulfilling their requirements with respect to the
Products. For clarity, Zeltiq shall have no obligation hereunder to respond to or otherwise interact 

  
 6 

ZELTIQ CONFIDENTIAL 

 
with any Customers in the Territory. The term “First-Level Support” means a level of support at least at the level that Certified Personnel are trained to provide in accordance with the
Zeltiq Training Program (as such terms are defined below). 
 (2) Distributor personnel shall participate in
Zeltiq’s standard training program applicable to the Products (“Zeltiq Training Program”) before selling any Products. The training will be provided at Zeltiq’s facilities unless another location is agreed by the parties.
Distributor shall be responsible for the travel-related costs and expenses of its personnel that attend the Zeltiq Training Program. Zeltiq and Distributor shall mutually agree to the number of Distributor personnel that must attend the Zeltiq
Training Program based on the size of the Territory, the number of potential customers in the Territory, and Distributor’s actual or potential sales of Products. 

(3) Distributor shall train all Customers with respect to the use of the Products in accordance with the then-current
requirements of the Zeltiq Training Program. Distributor shall only use training documentation provided by Zeltiq in performing Customer training. Distributor shall create and maintain a record of training for each Customer trained by Distributor
with respect to the Products substantially in the form attached hereto as Exhibit C (“Installation Record”).  
 (4) Distributor shall agree to participate and comply with the professional programs provided by Zeltiq (“Certified Partnership Program”). Zeltiq shall present the Certified Partnership
Programs within sixty (60) days of the Effective Date of this Agreement or within thirty (30) days of Distributor’s participation of the Zeltiq Training Program; whichever is earlier. 

(5) Distributor shall perform all Product service in accordance with the requirements set forth in the Zeltiq Training
Program and otherwise provided by Zeltiq to Distributor in writing from time to time during the Term, including requirements regarding Customer service response times, the provision of loaner Products, and similar matters. Distributor shall document
and maintain records of all Product service (“Service Records”) in accordance with the Zeltiq requirements identified in Exhibit D. Distributor shall offer and provide Product service (for Products in and out of warranty) to all Customers
in the Territory. With respect to out-of-warranty service, Distributor shall warrant its workmanship with respect to Product service for at least ninety (90) days after completion thereof. Distributor shall, within five (5) days after
Zeltiq’s request, provide Zeltiq with any or all Service Records. 
 (6) Zeltiq may in its sole discretion
provide Distributor with software enhancements and new features compatible with the Products (“New Features”). Distributor shall at its expense distribute the New Features to Customers in accordance with Zeltiq’s
instructions and shall support Customer installation thereof, unless Zeltiq provides written notice to Distributor that Zeltiq wishes to directly install or support such New Features, in which case Distributor shall provide Zeltiq with all
assistance reasonably requested by Zeltiq. Distributor shall create and maintain a record of each New Feature installation performed by Distributor as part of the Service Records. 

(i) Inventory. Distributor at a minimum shall purchase one (1) Service Unit at the time of the Initial Order
(as defined above “Minimum System Quota”). Distributor will purchase Service Units at a ratio of one (1) Zeltiq System for every fifteen (15) customer installations. Therefore, upon the 16th Customer installation, Distributor
shall purchase at a minimum its second Service Unit. Distributor shall not be required to purchase Consumables when securing Service Units. Distributor shall also purchase and maintain, without right of return (except as specified in
Section 5), an adequate inventory of Zeltiq Products for use in repairing Control Units and Applicators (as such terms are defined below) (“Spare Parts”), the adequacy of which shall be mutually determined by Zeltiq and Distributor.
Distributor may use such inventory for all repairs and replacements, whether or not covered under the Zeltiq warranty described in Section 5. If Distributor uses a Spare Part to service a claim under the Warranty, Zeltiq shall replace that part
in Distributor’s inventory upon return of a failed part to Zeltiq and after Zeltiq’s receipt of the Service Record applicable to such repair or replacement. Distributor shall report in writing the status of its inventory of Service Units
and Spare Parts to Zeltiq on each Forecast, Sales and Marketing Report. 

  
 7 

ZELTIQ CONFIDENTIAL 

 (j) Insurance. Distributor shall maintain during the term insurance
coverage consistent with industry standards for businesses engaged in the distribution of medical devices, including product liability, transportation (even by third parties) and product recall insurance. Upon Zeltiq’s request Distributor shall
provide certificate of insurance. 
 (k) Structure and Resources. Distributor undertakes that it has the
necessary structure and resources to support all the obligations contained herein and that no material investment shall be necessary for that purpose. 
  

	3.	RESPONSIBILITIES OF ZELTIQ 

 (a) Fulfillment of Product Orders; Warranty. Zeltiq shall fulfill orders for Products in accordance with Section 4 and shall replace or repair defective Products that are under warranty in
accordance with Section 5. 
 (b) Product Materials. Zeltiq shall provide Distributor the Product
Materials that Zeltiq generally provides to other distributors of the Products. All such materials shall be provided in the English language. Upon reasonable request by Distributor, Zeltiq agrees to supply all necessary documentation to enable
Distributor to comply with Government regulations in the Territory, including but not limited to safety testing documentation, clinical trial results, hazard and risk analysis documents and copies of Zeltiq’s technical file with respect to the
Products. 
 (c) Quality Systems. Zeltiq shall establish and maintain an ISO
13485 compliant quality system for the design and manufacture of the Products and shall comply with the obligations listed in Exhibit B of this Agreement. 

(d) New Products. The Products purchased by Distributor from Zeltiq under this Agreement shall be new unless
indicated otherwise by Zeltiq on a purchase order accepted by Zeltiq in accordance with this Agreement, provided that such Products may contain components that have been previously used in other Zeltiq product units. Products that contain such
previously used components shall meet or exceed Zeltiq’s written specifications for such Products. 
 (e)
Product Field Actions. From time to time Zeltiq may be required to effect a Product correction (e.g., a Field Safety Corrective Action) that requires removal of the Product from Customer premises or the provision of an advisory notice to
Customers, which correction is intended to reduce a risk of death or deterioration in the state of health associated with the use of a Product (each, a “Product Field Action”). If Zeltiq determines in its sole discretion that an
investigation by a government office or agency, regulatory authority or any other third party requires a Product Field Action, Zeltiq shall notify Distributor of such Product Field Action and Zeltiq shall perform such Product Field Action.
Distributor shall cooperate with, and provide assistance to, Zeltiq in connection with such Product Field Action, including locating and retrieving the Products, if necessary, and complying with the reasonable instructions of Zeltiq. Zeltiq shall
reimburse Distributor for all reasonable, documented third party out-of-pocket expenses incurred by Distributor in performing cooperation and assistance requested by Zeltiq in connection with Product Field Actions. 

  
 8 

ZELTIQ CONFIDENTIAL 

	4.	TERMS OF PURCHASE OF PRODUCTS BY DISTRIBUTOR 

 (a) Terms of Purchase of Products. All purchases of Products by Distributor from Zeltiq will be governed exclusively by the terms and conditions set forth in this Agreement and further defined in this
Section 4. 
 (b) Order, Acceptance and Cancellation. Distributor shall order Products by providing
written documentation “Purchase Orders” and shall reference the then current Product Prices (“Purchase Price”) as set forth in Exhibit A, Section 2. Zeltiq shall have the right to modify the Purchase Price at its sole
discretion upon forty-five (45) days written notice to Distributor. Zeltiq will notify Distributor of the acceptance of an order by written confirmation. Distributor may cancel product orders by providing written notice prior to Zeltiq’s
scheduled shipment of the Product(s) or within ten (10) business days of acceptance of Purchase Order, whichever is later. 
 (c) Taxes. The Purchase Prices do not include national, state or local excise, sales, use, value added or other taxes (“Taxes”) now or hereafter levied by any governmental
authority on the sale, purchase, transport or delivery of the Products. Distributor is responsible for all taxes associated with the order at the (time of the sale or thereafter). Distributor shall be responsible for reimbursement of any and all
Taxes paid by Zeltiq within thirty (30) days of shipment. 
 (f) Payment. All orders will be
prepaid prior to shipment via wire transfer or letter of credit. 
 (g) Shipping. Terms of transportation
and delivery of product is EX-WORKS at Zeltiq’s facility. In addition to Distributor’s responsibility to pay for all costs associated with insurance, freight, import/export charges, and similar costs and expenses related to the shipment or
the Products; Distributor shall pay a packaging fee to Zeltiq totaling Five Hundred U.S. Dollars (US $500) for each Control Unit that is purchased. Zeltiq shall select a freight forwarder or carrier (“Carrier”) unless Distributor
designates Carrier within the Purchase Order. Upon delivery of each Product to the Carrier, the title will transfer to Distributor, and deemed accepted by the Distributor without right of return. Zeltiq will have no further obligation or liability
with respect to the delivery of such Product. 
  

	5.	PRODUCT WARRANTY 

 (a) Control Unit Warranty. The warranty period for the control unit (“Control Unit”) shall be three (3) years following the earlier of (i) the date on which Distributor has
installed the Control Unit and (ii) the date that is sixty (60) days after the date Zeltiq ships the Control Unit to Distributor (or to Customer, if the Control Unit is drop shipped) pursuant to a Purchase Order (“Standard Control
Unit Warranty Period”). Zeltiq warrants to Distributor during the Standard Control Unit Warranty Period, and subject to the provisions of this Section 5 (Product Warranty), that the Control Unit will be free from material defects in
materials and workmanship and will substantially conform to Zeltiq’s written specifications applicable to the Control Unit as such specifications exist on the date of shipment (“Control Unit Warranty”). 

(b) Applicator Warranty. The warranty period for the applicator (“Applicator”, excluding the associated
replaceable Procedure Cards “Procedure Cards”) shall be one (1) year following the earlier of (i) the date on which Distributor has installed the Applicator and (ii) the date that is sixty (60) days after the date
Zeltiq ships the Applicator to Distributor (or to Customer, if the Applicator is drop shipped) pursuant to a Purchase Order (“Standard Applicator Warranty Period”). Zeltiq warrants to Distributor during the Standard Applicator Warranty
Period, and subject to the provisions of this Section 5 (Product Warranty), that the Applicator will be free from material defects in materials and workmanship and will substantially conform to Zeltiq’s written specifications applicable to
the Applicator as such specifications exist on the date of shipment (“Applicator Warranty”). 
 (c)
Procedure Card Warranty. The warranty period for the Procedure Cards shall be for the useful life of Procedure Cards, which period shall begin on the date Zeltiq ships the applicable 

  
 9 

ZELTIQ CONFIDENTIAL 

 
Procedure Cards to Distributor (or to Customer, if the Procedure Cards are drop shipped) pursuant to a Purchase Order (the “Procedure Card Warranty Period”). Zeltiq warrants to
Distributor during the Procedure Card Warranty Period and subject to the provisions of this Section 5 that the applicable Procedure Cards will be free from material defects in materials and workmanship and will substantially conform to
Zeltiq’s written specifications applicable to the Procedure Cards as such specifications exist on the date of shipment (“Procedure Card Warranty”). 

(d) Software Updates. During the Control Unit and Applicator Warranty Period, Zeltiq shall make available to
Distributor, at no additional charge, all bug fixes and error corrections for the software for the Control Units and Applicators subject to such warranties that Zeltiq makes available at no additional charge to other customers in the Territory
receiving such warranty services. 
 (e) RMA Procedure. In the event of a breach of the Control Unit and
Applicator Warranty, or the Procedure Card Warranty, Zeltiq shall, at its option and expense, either: (i) accept return of the defective Product and repair or have repaired the defective Product, or (ii) accept return of the defective
Product and provide a replacement Product to Distributor. Distributor must obtain a Return Material Authorization (“RMA”) number from Zeltiq prior to returning any Product to Zeltiq and must otherwise follow Zeltiq’s then-current RMA
procedure in connection with any such return. If Zeltiq determines in its reasonable discretion that any Product returned by Distributor conforms to the applicable warranty (“Non-Defective Products”), Zeltiq will notify the Distributor of
such and will return the applicable Product to Distributor at Distributor’s expense. In addition, Zeltiq may assess Distributor a charge for testing and examination of Non-Defective Products. The repair or replacement of Products in accordance
with this Section 5(e) shall be Zeltiq’s entire liability and Distributor’s sole and exclusive remedy for Zeltiq’s breach of the Control Unit Applicator Warranty and the Procedure Card Warranty. 

(f) Labor and Shipping Costs. Distributor shall be responsible for and shall perform all labor required in
connection with the warranty services described in this Section 5 (excluding labor associated with the repair or replacement of Products at Zeltiq’s facilities), including labor required to inspect Products on Customers’ premises and
to ship Products to Zeltiq. Distributor shall be responsible for and pay all freight, insurance, import/export and other shipping-related charges to Zeltiq for all warranty repairs. Products returned to Zeltiq by Distributor must be shipped D.D.P.
(Incoterms 2000) Zeltiq’s facility or such other location as Zeltiq may designate. Zeltiq shall be responsible for and pay all freight, insurance, import/export and other shipping-related charges to return repaired Products to Distributor,
provided that if Zeltiq determines that any Product returned for warranty repair is not defective, Distributor shall pay such charges. 
 (g) No Contact with Customers. The Control Unit and Applicator Warranty and the Procedure Card Warranty (collectively, “Warranties”) are solely for the benefit of Distributor. Nothing in
this Section 5 or elsewhere in this Agreement obligates Zeltiq to accept Product returns directly from Customers or otherwise provide warranty or other services to any Customers. Unless otherwise directed by Zeltiq, Distributor shall handle all
interactions with Customers regarding warranty services and Products in connection with this Agreement. Distributor shall make no warranties, representations, guarantees or statements to Customer or other third parties that suggest that Zeltiq has
any warranty or service obligation to, or any contractual privity with, any recipient of a Product. 
 (h)
Limitations. The Warranties are the only warranties made by Zeltiq with respect to the Products. Distributor shall not make any warranties, representations, guarantees or statements regarding the Products that exceed the scope of the
Warranties, and Distributor shall be exclusively responsible for any obligations or other liability arising from any such warranties, representations, guarantees or statements made by Distributor or its agents. The Warranties are not transferable to
any third party. The Warranties do not apply and will be void if the conditions set forth in this Section 5 are not met, or if the Control Unit, Applicator or Procedure Card has been subjected to improper operation, has had unauthorized repair
or modification (including the installed or provided software), or has been subjected 

  
 10 

ZELTIQ CONFIDENTIAL 

 
to neglect or abuse (including mechanical shocks, failure to maintain the Control Unit, Applicator or Procedure Card, use with expired or unauthorized Supplies, improper transport, mechanical or
electrical shock, operation outside of its environmental specifications and otherwise), willful damage, negligence, abnormal working conditions, failure to follow Zeltiq’s instructions (whether oral or in writing), misuse or alteration or
repair of the Products without Zeltiq’s written approval. Zeltiq shall not be obligated under the Warranties with respect to Products located outside the Territory or for any claims made after the expiration of the applicable warranty period.

 (i) Disclaimer. EXCEPT FOR THE WARRANTIES,
ZELTIQ MAKES NO WARRANTIES OR REPRESENTATIONS WITH RESPECT TO THE PRODUCTS,
ANY TRAINING, AND ANY SERVICES PROVIDED UNDER THIS AGREEMENT, AND ZELTIQ
HEREBY DISCLAIMS ALL OTHER WARRANTIES AND REPRESENTATIONS OF ANY NATURE, EXPRESS
OR IMPLIED, INCLUDING ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, AND NON-INFRINGEMENT. THE WARRANTIES ARE EXCLUSIVE AND IN LIEU
OF ALL OTHER WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE. 

 

	6.	TERM AND TERMINATION 

 (a) Term. The Term shall commence on the Effective Date and shall continue for three (3) years thereafter, unless terminated earlier under the provisions of this Section 6 (the
“Initial Term”). This Agreement may be extended for renewal terms by a written agreement executed by both parties (each, a “Renewal Term”). The Initial Term together with any Renewal Terms agreed by the
parties constitute the “Term.” Upon Zeltiq’s request, Distributor shall provide a copy of its most recent year-to-date income statement, balance sheet, and cash-flow statement. The effective date of any expiration or
termination of this Agreement under this Section 6 is referred to as the “Termination Date.” 
 (b) Termination for Cause. If either party materially defaults in the performance of any provision of this Agreement including, but not limited to Sections 1(b), 1(e), 1(h), 2(d), 2(e), 2(f), and
8, the non-defaulting party may give written notice to the defaulting party that if the default is not cured within thirty (30) days of such notice, the non-defaulting party may terminate the Agreement. If the non-defaulting party gives such
notice and the default is not cured during the thirty (30) day period, this Agreement shall automatically terminate at the end of such period without further action by the non-defaulting party, unless, in the case of a default by Distributor,
Zeltiq notifies Distributor of a specific effective date for termination in which case such date shall be the Termination Date. 
 (c) Termination for Insolvency. Zeltiq may terminate this Agreement effective upon written notice to Distributor (i) upon the institution by or against Distributor of insolvency, receivership,
liquidation, moratorium, bankruptcy or similar proceedings or any other proceedings for the settlement of Distributor’s debts, (ii) upon Distributor’s making an assignment or compromise for the benefit of creditors or a similar
proceeding, or (iii) upon Distributor’s dissolution or ceasing to do business. Distributor shall notify Zeltiq of any event described in clauses (i) through (ii) above no later than ten (10) days after the occurrence of such
an event. 
 (d) Termination upon a Change of Control of Zeltiq. If Zeltiq undergoes a Change of Control
(as defined below) at any time on or following the two (2) year anniversary of the date of this Agreement, then Zeltiq may terminate this Agreement by giving at least six (6) months written notice (the “Change of Control Notice”)
of the Termination Date to Distributor. In the event of a termination pursuant to this Section 6(d), then until the earlier of (i) the expiration of the Term of the Agreement pursuant to Section 6(a) above, or (ii) the end of the
six (6) month period following the Termination Date, Distributor and Zeltiq, including Zeltiq’s successors and assigns, shall be co-exclusive distributors of the Products during such period; provided that Zeltiq and its successors or
assigns shall not sell Products to existing accounts of Distributor during the remaining months of the Initial Term. The term “Change of 

  
 11 

ZELTIQ CONFIDENTIAL 

 
Control” shall mean, with respect to any party, such party’s direct or indirect acquisition by, or merger with, a third party, the sale of all or substantially all of the assets of such
party, or a transaction pursuant to which the owners or shareholders of such party that hold more than fifty percent (50%) of such party’s equity or other ownership interest prior to the transaction cease to own at least fifty percent
(50%) of such interest after the transaction; provided that a Change of Control shall not include any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by such party or any
successor or indebtedness of such party is cancelled or converted or a combination thereof. 
 (e)
Termination for Change of Control of Distributor. If Distributor undergoes a Change of Control, Distributor shall promptly notify Zeltiq of such event and Zeltiq may terminate this Agreement by giving at least sixty (60) days written
notice of the Termination Date to Distributor. Distributor shall notify Zeltiq of any Change of Control or potential Change of Control as soon as legally possible, and in no event later than ten (10) days after the closing of such an event.

 (f) Fulfillment of Orders upon Termination. After the Termination Date Zeltiq shall be obligated to
fulfill only those orders that were accepted by Zeltiq prior to the Termination Date, provided that Zeltiq shall have no such obligation if Zeltiq terminates this Agreement pursuant to Sections 6(b) through (e). 

(g) Records, Products, and Zeltiq Marks. Within ten (10) days after the Termination Date, Distributor shall
provide to Zeltiq all of the most current versions of the following documents: Sales Records, Training Records, Service Records, Update Reports, Warranty Service Reports, and Customer Agreements. Zeltiq shall also have the right, but not the
obligation, to (a) purchase or (b) broker the transfer to a distributor of Zeltiq’s choosing any inventory of Products in Distributor’s possession on the Termination Date at the Purchase Prices paid by Distributor for such
Products (“Remaining Inventory”). Distributor shall have the right for ninety (90) days after the Termination Date to sell all or a portion of the Remaining Inventory Zeltiq chooses not to so purchase or broker. Any Remaining
Inventory that (x) Zeltiq chooses to purchase or to broker or (y) Distributor has not sold within such ninety (90)-day period shall be shipped by Distributor at Zeltiq’s direction and reasonable expense to a location designated by
Zeltiq. Effective upon the Termination Date, Distributor shall cease its use of all applications/registrations of the Products (if applicable), trademarks, service marks, trade names, URLs, domain names, and other brand identifiers of Zeltiq and
shall cease representing to any third party that it is affiliated in any way with Zeltiq. Notwithstanding the foregoing, the Distributor shall be entitled to retain copies of materials described in this section and to continue to use such materials
and trademarks solely as necessary to fulfill its obligations under Section 6(h). 
 (h) Service
Responsibility after Termination Date. To the extent reasonably requested by Zeltiq in writing, Distributor shall continue to provide installation, warranty and other Product service to existing Customers with respect to the Products for a
period designated by Zeltiq of up to two (2) months after the Termination Date. Any such installation, warranty and other service rights will be on a non-exclusive basis and may be extended upon written agreement by Zeltiq and Distributor.
Except as set forth in this Section 6(h), Distributor shall cease providing service or otherwise interacting with Customers with respect to the Products as of the Termination Date. Distributor shall assign to Zeltiq any Customer Agreements
designated by Zeltiq promptly upon Zeltiq’s request in connection with any termination or expiration of this Agreement. 
 (i) Limitation on Liability Upon Termination. IN NO EVENT SHALL ZELTIQ BE LIABLE
TO DISTRIBUTOR FOR ANY COMPENSATION, REIMBURSEMENT, DAMAGES OR OTHER LIABILITY
ARISING FROM THE EXPIRATION OR TERMINATION OF THIS AGREEMENT IN ACCORDANCE
WITH THIS SECTION 6, INCLUDING LOSS OF PROSPECTIVE PROFITS OR ANTICIPATED SALES
OR ON ACCOUNT OF EXPENDITURES, INVENTORY, INVESTMENTS, LEASES OR COMMITMENTS IN
CONNECTION WITH THE BUSINESS OR GOODWILL. FOR CLARITY, ANY TERMINATION OR
EXPIRATION SHALL NOT RELIEVE EITHER PARTY OF OBLIGATIONS INCURRED PRIOR TO
THE TERMINATION DATE. 

  
 12 

ZELTIQ CONFIDENTIAL 

 (j) Survival of Certain Terms. All definitions and the provisions of
Sections 2-6, 8, 10 and 11 shall survive the termination or expiration of this Agreement for any reason. All other rights and obligations of the parties shall cease upon termination of this Agreement; provided however, the terms of the Customer
Agreements shall survive in accordance with their own terms. 
 7. LIMITED LIABILITY. IN NO
EVENT WILL ZELTIQ OR ITS LICENSORS OR SUPPLIERS BE LIABLE FOR LOST
PROFITS OR SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR
RELATED TO THIS AGREEMENT (WHETHER FROM BREACH OF CONTRACT, BREACH OF
WARRANTY, OR FROM NEGLIGENCE, STRICT LIABILITY, OR ANY OTHER FORM OF
ACTION), EVEN IF ZELTIQ HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES, OTHER THAN FOR FRAUD OR WILLFUL MISCONDUCT. THIS LIMITATION OF LIABILITY
SHALL APPLY NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED
REMEDY HEREIN. OTHER THAN WITH RESPECT TO ANY LIABILITY FOR FRAUD OR
WILLFUL MISCONDUCT, IN NO EVENT WILL ZELTIQ’S AGGREGATE, CUMULATIVE LIABILITY
ARISING OUT OF OR RELATED TO THIS AGREEMENT EXCEED THE SUM OF
ALL FEES ACTUALLY PAID TO ZELTIQ BY DISTRIBUTOR PURSUANT TO SECTION 4
DURING THE ONE (1) YEAR PERIOD IMMEDIATELY PRECEDING THE FIRST EVENT GIVING
RISE TO LIABILITY. THIS LIMITATION OF LIABILITY IS CUMULATIVE, WITH ALL
PAYMENTS BEING AGGREGATED TO DETERMINE SATISFACTION OF THE LIMIT. THE EXISTENCE
OF TWO OR MORE CLAIMS OR SUITS WILL NOT ENLARGE THIS LIMIT.
IN NO EVENT WILL ZELTIQ HAVE ANY LIABILITY WHATSOEVER UNDER THIS
AGREEMENT TO CUSTOMERS. THE PARTIES ACKNOWLEDGE THAT THE PRICES SPECIFIED IN
THIS AGREEMENT REFLECT THE ALLOCATION OF RISK SET FORTH IN THIS
AGREEMENT AND THAT ZELTIQ WOULD NOT ENTER INTO THIS AGREEMENT WITHOUT
THE FOREGOING LIMITATIONS OF ITS LIABILITY AND THE WARRANTY DISCLAIMERS CONTAINED
HEREIN. 
  

	8.	PROPRIETARY RIGHTS AND CONFIDENTIALITY 

 (a) Proprietary Rights. Distributor agrees that Zeltiq owns all right, title, and interest in the Products and in all of Zeltiq’s patents, registrations, filings, applications, trademarks,
trade names, inventions, copyrights, know-how, trade secrets and other intellectual property relating to the design, manufacture, operation or service of the Products. Zeltiq grants Distributor a license to sell the Products and to use the Products
solely as necessary to perform its obligations under this Agreement. Except for the foregoing license, the sale of the Products hereunder to Distributor does not and will not be deemed to confer upon Distributor any right, interest or license in any
patents or patent applications, or copyrights or other proprietary rights that Zeltiq or any third party may have in the Products or otherwise and shall not confer on Distributor any right to manufacture or have manufactured, duplicated or otherwise
copied or reproduced any of the Products or any part or component thereof. Zeltiq shall retain exclusive ownership of all proprietary rights in and to all documentation and other data and materials pertaining to any Products. All rights not
expressly granted to Distributor in this Agreement are reserved by Zeltiq. 
 (b) Software. As between
the parties, Zeltiq owns and shall retain all right, title and interest in the software and firmware contained in the Products (“Software”). Notwithstanding any other provision of this Agreement, the Software is licensed to, and not sold
to Distributor, pursuant to the license set forth below. Any references to “sale” or “purchase” in this Agreement with respect to the Software mean the sale or purchase of such license to the Software, and not that the Software
itself is sold or purchased. Subject to Distributor’s compliance with this Agreement, Zeltiq grants Distributor a non-exclusive, non-transferable license to reproduce and distribute the Software solely as necessary for Distributor to distribute
and service the Products in accordance with this Agreement. 

  
 13 

ZELTIQ CONFIDENTIAL 

 (c) Reverse Engineering. Except where such restriction is expressly
prohibited by law, Distributor will not reverse engineer or otherwise attempt to derive or obtain information about the functioning, manufacture or operation of the Products, including the Software therein. 

(d) Confidentiality. Zeltiq may disclose certain Confidential Information (as defined below) to Distributor to
permit Distributor to perform its obligations under this Agreement. Distributor shall not use any Confidential Information for any purposes or activities other than those specifically authorized in this Agreement, and shall not disclose any
Confidential Information to third parties without Zeltiq’s prior written approval. The foregoing use and disclosure restrictions with respect to Confidential Information shall apply during the Term and for a period of three (3) years after
the Termination Date. “Confidential Information” means all non-public data and information of Zeltiq, including any proprietary information, technical data, trade secrets or know how, including research, product plans, products, services,
customers, customer lists, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances or other business information of Zeltiq communicated,
orally, electronically, or in writing, to Distributor. The foregoing provisions shall not apply, or shall cease to apply, to Confidential Information if such information that: (i) is known to Distributor at the time of disclosure to Distributor
by Company as evidenced by written records; (ii) becomes public knowledge without a breach of confidence by Distributor or any third party; (iii) is disclosed to Distributor by a third party lawfully entitled to make such disclosure;
(iv) is independently developed by Distributor; or (v) is required to be disclosed pursuant to any statutory or regulatory provision or court order (provided that Distributor promptly notifies Zeltiq of such potential required disclosure
and assists Zeltiq in preventing or limiting such disclosure). The Distributor shall have the burden of establishing any of the foregoing exceptions by clear and convincing evidence. Without limiting the foregoing, Distributor shall not publish any
technical description of the Products beyond the descriptions published publicly by Zeltiq. Distributor shall return or destroy all Confidential Information in Distributor’s possession within ten (10) days after the Termination Date
(except as required to perform Distributor’s obligations under Section 6(h)) and, upon Zeltiq’s request, shall certify in a writing signed by an officer of Distributor that it has done so. 

 

	9.	TRADEMARKS AND TRADE NAMES 

 (a) Use. During the Term, and subject to the terms and conditions of this Agreement, Distributor shall have the right in the Territory to indicate to the public that it is an authorized distributor
of the Products and to advertise the Products in the Territory under the trademarks, marks, and trade names specified on Exhibit E (“Zeltiq Trade-names”). Distributor shall not use any of Zeltiq Trade-names as part of its business name or
as part of prominent signage displaying Distributor’s business name. Distributor shall not create new service or trademarks or trade-names based in whole or in part on the Zeltiq Trade-names. Distributor shall not alter or remove any of Zeltiq
Trade-names applied to the Products by Zeltiq. Nothing herein shall grant to Distributor any right, title or interest in Zeltiq Trade-names. Distributor acknowledges Zeltiq’s ownership of and rights in the Zeltiq Trade-names and the validity of
all registrations therefore, and agrees to take no action contrary to such ownership and rights during the Term and thereafter. Distributor will assist Zeltiq, if requested, by providing documentation of use of the Zeltiq Trade-names in connection
with any trademark or service mark application. Distributor shall not attempt to register the Zeltiq Trade-names without prior written approval from Zeltiq. In the event that any infringement of any of Zeltiq Trade-names shall come to
Distributor’s attention, Distributor shall promptly inform Zeltiq thereof. Zeltiq, in its sole discretion, shall determine whether or not to initiate or pursue proceedings against any such infringer. Nothing in this Section 9 is to be
construed as a representation or guarantee by Zeltiq that Distributor’s use of Zeltiq Trade-names in the Territory will not infringe the rights of others. At any time during this Agreement should Distributor challenge or assist others to
challenge Zeltiq Trade-names or the registration thereof or attempt to register any trade marks, or trade names confusingly similar to those of Zeltiq Trade-names, Zeltiq shall have the right to terminate this Agreement upon written notice to
Distributor. 

  
 14 

ZELTIQ CONFIDENTIAL 

 (1) Customer Use. Upon completion of training by Distributor to
Customer, Customer shall become an authorized provider of Zeltiq Products and authorized to use the Zeltiq Marks solely in its promotion and delivery of services utilizing Zeltiq Products. Customer acknowledges Zeltiq’s exclusive ownership of
the Zeltiq Marks and that its use thereof inures solely to Zeltiq’s benefit. Customer shall not attempt to obtain registration of any Zeltiq Mark, and shall not debrand, rebrand or private label any Zeltiq Product or service. Distributor shall
have sole responsibility to notify Customer in writting of these terms upon Sale of Zeltiq Products. Distributor is required to notify Zeltiq immediately of any misuse or violation of Zeltiq Marks and its Products as defined within this Section. Any
misuse or violation of this section may result in termination of Sale and/or forfeit of Product. 
 (b) Approval. All
representations of Zeltiq Trade-names that Distributor intends to use or publish shall (i) use the appropriate trademark symbol and legends in conjunction therewith, (ii) shall first be submitted to Zeltiq for approval (which shall not be
unreasonably withheld) of design, color, and other details, or shall be exact copies of Zeltiq Trade-names, and (iii) shall otherwise comply with Zeltiq’s then-current trademark guidelines provided to Distributor from time to time during
the Term. Distributor agrees to provide to Zeltiq copies, in English and any language into which the materials have been translated in accordance with this Agreement, prior to any public use of the materials. Distributor shall modify any such
materials and activities to ensure compliance with this Agreement upon Zeltiq’s request. 
  

	10.	INDEMNIFICATION 

 (a) By Zeltiq. Notwithstanding anything to the contrary herein, subject to Distributor’s obligations set forth below in Section 10(c) (“Indemnification Procedure”), Zeltiq
hereby agrees to indemnify, defend and hold harmless Distributor from and against all third party claims, damages, losses, costs and expenses, including reasonable attorneys’ fees (“Claims”), arising out of or relating to injury,
illness, or death of any person, or damage to any property, to the extent arising out of or resulting from (A) a material defect in, material malfunction of, or undocumented or insufficiently or incorrectly documented risks resulting from usage
of, the Products in the form provided by Zeltiq and pursuant to their prescribed use and nonprescribed use (for so long as Distributor does not market the products for nonprescribed use) or (B) Zeltiq’s negligence or willful misconduct; or
(C) any third party claim that Products, as supplied hereunder, infringe or misappropriate any third party patents; provided that Zeltiq will have no obligation under subsection (C) above for any such Claim that arises out of (i) the
modification of the Products by any party other than Zeltiq, (ii) the combination of the Products with any other hardware, device, or software not supplied by Zeltiq where the Claim is directed at the combination, or (iii) infringement of
patent claims covering completed equipment or any assembly, circuit, combination, method or process in which any of the Products may be used but not covering the Products standing alone. Zeltiq shall pay any damages, costs, and expenses finally
awarded to a third party by a court or in a settlement agreed to by Zeltiq arising from such Claims. If the Products become, or in Zeltiq’s opinion are likely to become, the subject of any infringement claim, Zeltiq may, at its option and
expense, either (x) procure for Distributor the right to continue using the Products; (y) replace or modify the Products so they become non-infringing; or (z) accept return of the Products and remove the infringing Products from
Exhibit A, Section 2. The foregoing indemnification obligations are Distributor’s sole and exclusive remedy, and Zeltiq’s entire liability, for any claims of intellectual property infringement by the Products. 

  
 15 

ZELTIQ CONFIDENTIAL 

 (b) By Distributor. Subject to the Indemnification Procedures,
Distributor will defend Zeltiq with respect to any Claim brought against Zeltiq by a third party to the extent that such Claim arises from or is related to (i) Distributor’s use, marketing, resale, or distribution of the Products
(excluding any Claims covered under the indemnity in Section 10(a)), (ii) a breach by Distributor of Section 2, (iii) translations of Zeltiq marketing, technical and other materials (to the extent liability is caused by the
translation and not the material in their original form), or (iv) Distributor’s sale or distribution of Products outside the Territory. Distributor will pay any damages, costs, and expenses finally awarded to a third party by a court or in
a settlement agreed to by Distributor arising from such Claims. 
 (c) Indemnification Procedure. The
party seeking indemnification (the “Indemnified Party”) shall: (i) give the indemnifying party (the “Indemnifying Party”) notice of any Claim subject to indemnification under this Section 10; (ii) cooperate with
the Indemnifying Party, at the Indemnifying Party’s expense, in the defense of such Claim; (iii) shall provide the Indemnifying Party with reasonable access to information about the Indemnified Party and such Claim and the reasonable
assistance of the officers and employees of the Indemnified Party for purposes of exercising the rights under this Section 10; and (iv) give the Indemnifying Party the right to control the defense and settlement of any such claim. The
Indemnified Party will have the right to participate in the defense with counsel of its choice at its own expense, provided that the Indemnifying Party will have the right to make final decisions regarding the defense of a Claim as long as the
Indemnifying Party actively maintains the defense of such Claim. 
  

	11.	GENERAL PROVISIONS 

 (a) Governing Law. This Agreement will be governed in all respects by the laws of the State of California, U.S.A. without regarding to conflicts of law principles that would require the application
of the laws or any other jurisdiction. Both parties consent to the personal jurisdiction of the courts located in Alameda County, California and further agree that any cause of action arising out of or relating to this Agreement shall be brought
exclusively in a U.S. federal or California state court located in Alameda County, California; provided that Zeltiq may bring an action in any jurisdiction in order to enforce its intellectual property rights, rights of exclusivity, and other rights
and remedies under this Agreement. The United Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement. 
 (b) Severability; Waiver. If any provision of this Agreement is held to be invalid or unenforceable for any reason for a court of competent jurisdiction, the remaining provisions will continue in
full force without being impaired or invalidated in any way. The failure of either party to insist upon strict performance of any provision of this Agreement, or to exercise any right provided for herein, shall not be deemed to be a waiver for the
future of such provision or right, and no waiver of any provision or right shall affect the right of the waiving party to enforce any other provision or right herein. 

(c) Notices. Any notice or communication permitted or required hereunder will be in writing and will be delivered
by facsimile transmission with confirmation of receipt, in person or by courier, or mailed by certified or registered mail, postage prepaid, return receipt requested (“Mail”), and addressed as set forth in the preamble to this Agreement or
to such other facsimile number or address as either party may provide from time to time to the other. If notice is given in person, by courier, by facsimile or by electronic mail (email), it will be effective upon receipt; and if notice is given by
Mail, it will be effective three (3) business days after deposit in the Mail. 
 (d) Force Majeure.
If performance of this Agreement, or any obligation hereunder (other than the obligation to pay) is prevented, restricted, or interfered with by any act or condition whatsoever beyond the reasonable control of the affected party (including the
failure of any suppliers to perform), the party so affected, upon giving prompt notice to the non-affected party, will be excused from such performance to the extent of such prevention, restriction, or interference. 

  
 16 

ZELTIQ CONFIDENTIAL 
  

 (e) Construction. Section headings are provided solely for reference
purposes and in no way define, limit, interpret, or describe the scope or extent of such section or in any way affect this Agreement. When used in this Agreement, the term “including” means “including without limitation” unless
expressly stated to the contrary. 
 (f) Privacy Authority. Distributor irrevocably authorizes Zeltiq,
its employees and agents to make such inquiries as it deems necessary to investigate the credit worthiness or other information requirements of Distributor from time to time including the making of inquiries of persons that are trade references, the
bankers of Distributor or any other credit providers (collectively the “Information Sources”) and Distributor hereby authorizes the Information Sources to disclose to Zeltiq such information concerning Distributor. 

(g) Assignment. Distributor may not assign, delegate or otherwise transfer any right or obligation of Distributor
under this Agreement whether by agreement, operation of law, or otherwise, without the express prior written consent of Zeltiq; provided, however, that Distributor may assign, delegate or otherwise transfer any right or obligation hereunder to its
parent and any of its subsidiaries or affiliates. Any purported assignment, delegation, or transfer in violation of the previous sentence will be null and void. Subject to the foregoing, this Agreement in its entirety will bind each party and its
permitted successors and assigns. 
 (h) Amendments. Any amendments, modifications, supplements, or other
changes to this Agreement must be in writing and signed by duly authorized representatives of each party. 
 (i)
Entire Agreement. This Agreement and the exhibits hereto constitute the entire agreement between the parties with respect to the subject matter hereof, and supersedes all prior or contemporaneous representations, understandings, agreements,
or communications between the parties, whether written or oral, relating to the subject matter hereof. 
 (j)
Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed to be an original, and all of which together will constitute one instrument. 

  
 17 

ZELTIQ CONFIDENTIAL 
  

 IN WITNESS
WHEREOF, the parties have caused their duly authorized representatives to execute this Distribution Agreement as of the Effective Date. 

 

					
	“Zeltiq”	    	“Distributor”	 	
			
	ZELTIQ AESTHETICS, INC.	    	 ADVANCE Medical, Inc
	 	
			
	 /s/ John Howe
	    	 /s/ Fred Aslan
	 	
	 By
	    	 By
	 	
			
	 John Howe
	    	 Fred Aslan
	 	
	 Chief Financial Officer
	    	 Chief Executive Officer
	 	

  
 18 

ZELTIQ CONFIDENTIAL 
  

 EXHIBIT A 

 

	1.	TERRITORY 

Exclusive: Brazil 
 Non-Exclusive: N/A 
  

	2.	PRODUCTS & PRICES 

  

									
	 Product Name
	  	 Catalog Number
	  	Distributor
Price	 	 	 Additional Details

	Control Unit & county Kit
				
	Zeltiq Breeze Control Unit	  	BRZ-CG1-CUB-1 10V	  	$	[***	] 	 	 [***]

				
	Zeltiq Breeze County Kit – Brazil	  	BRZ-RP1-KIT-BR	  	$	[***	] 	 	 [***]

	
	Applicators
				
	eZ App 6.2	  	BRZ-AP1-062-000	  	$	[***	] 	 	[***]
	eZ App 6.3	  	BRZ-AP1-063-000	  	$	[***	] 	 	[***]
	eZ App 8.0*	  	BRZ-AP1-080-000	  	$	[***	] 	 	[***]
	
	Consumables
	
	6 Series
				
	Zeltiq eZ Card 6 Starter Pack – 12 Cycle	  	BRZ-SP2-06X-012	  	$	[***	] 	 	 [***]

	Zeltiq eZ Liner 6 – Pack, 24 Cycle	  	BRZ-SP2-06X-024	  	$	[***	] 	 	 [***]

	Zeltiq eZ Liner 6 – Qty 16	  	BRZ-LN1-06X-016	  	$	[***	] 	 	 [***]

	Zeltiq eZ Liner 6 – Qty 12	  	BRZ-LN1-06X-016	  	$	[***	] 	 	 [***]

	
	8 Series*
				
	Zeltiq eZ Card 8 Starter Pack – 8 Cycle	  	BRZ-SP2-08X-080	  	$	[***	] 	 	 [***]

	Zeltiq eZ Card 8 – Pack, 16 Cycle	  	BRZ-RP2-08X-016	  	$	[***	] 	 	 [***]

	Zeltiq eZ Pad 8 – Qty 8	  	BRZ-PD1-08X-008	  	$	[***	] 	 	 [***]

	Zeltiq eZ Liner 8 – Qty 8	  	BRZ-LN1-08X-008	  	$	[***	] 	 	 [***]

	
	Accessory Packs and Brochures
				
	Applicator Cable Support Arm	  	BRZ-RP1-ARM-001	  	$	[***	] 	 	 [***]

	Patient Brochure - Female	  	BRZ-RP1-BRO-001	  	$	[***	] 	 	 [***]

	Patient Brochure - Male	  	BRZ-RP1-BRO-002	  	$	[***	] 	 	 [***]

	Support Pack	  	BRZ-SUP-PCK-001	  	$	[***	] 	 	 [***]

	Practice Enhancement Pack	  	BRZ-PEP-PCK-001	  	$	[***	] 	 	 [***]

	Photography Pack	  	BRZ-PHO-PCK-001	  	$	[***	] 	 	 [***]

	Tripod	  	BRZ-TRI-PCK-001	  	$	[***	] 	 	 [***]

  
 19 

ZELTIQ CONFIDENTIAL 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with
respect to the omitted portions. 

	3.	QUARTERLY SYSTEM QUOTA 

  

																									
	 Calendar Year
	  	 	 	 	Q1	 	 	Q2	 	 	Q3	 	 	Q4	 	 	Total	 
	 First Year Quota (2011) (including Initial Order)
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Second Year Quota (2012)*
	  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Third Year Quota (2013)*
	  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Remaining Term of Agreement (2014)*
	  				 				 				 				 				 			

  

	*	Second and Third Year Quotas are estimates with commitments established for these years 60 days prior to the start of each calendar year. 

  
 20 

ZELTIQ CONFIDENTIAL 

[***] Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential Treatment has been requested with
respect to the omitted portions. 

 EXHIBIT B 
 Quality and Regulatory Roles and Responsibilities of Zeltiq and Distributor 
  

					
	 (a) Element
	  	 (b) Responsibility

	  	 Zeltiq
	  	 Distributor

	 Maintain an ISO 13485 compliant Quality System
	  	X	  	
			
	 Maintain Certificate of Exportability from FDA (if applicable)
	  	X	  	
			
	 Provide to Distributor and maintain any design dossiers or technical files necessary to support licensing and distribution within the Territory.
	  	X	  	
			
	 File for and maintain appropriate licenses to permit legal distribution within the Territory. Provide copies of said licensing to Zeltiq.
	  		  	X
			
	 Handling, Storage and Distribution: Maintain adequate storage facilities to prevent adverse impact to product such as deterioration.
	  		  	 X
  

In transit from Zeltiq to local warehouse and during transit to end customer

			
	 Maintain distribution records that contain the following information:

 

•    The name and address of the initial consignee;

 
 •    The
identification and quantity of devices shipped;
  
 •    The date shipped; and
  

•    Serial and/or lot number shipped.
	  	 X
  

Consignee is Distributor
	  	 X
  

Consignee is the end-customer

			
	 Provide distribution and installation records (including the results of any required testing) to Zeltiq on a quarterly basis.
	  		  	X
			
	 Notify Zeltiq within 24 hours of the occurrence of any complaint. A complaint, includes, but is not limited to the
following events:
  

•    Alleged or actual Product malfunction;

 
 •    Alleged or
actual injury to patients or operators (even if caused by use error);
  
 •    Potential counterfeiting;
  

•    Non-routine servicing or installation.

 
 This notification shall include the following information:

 

•    The name of the device

 
 •    The date the
complaint was received;
  

•    The date the event occurred;

 
 •    The serial
number and/or lot number of the device;
  
 •    The name, address, and phone number of the physician;
  

•    Description of the complaint (What happened?);

 
 •    Whether or not
the patient or operator experienced an injury and, if so, the nature of the injury.
	  		  	X

  
 21 

ZELTIQ CONFIDENTIAL 
  

 EXHIBIT C 
 INSTALLATION RECORD 

  
 22 

ZELTIQ CONFIDENTIAL 
  

 Zeltiq Aesthetics – Confidential and Proprietary 

 

							
	 Part Number: FM10798
	  	 Revision: H
	  	 Page 1 of 1
	  	 
	 Title: Form, Device
Installation

	 
	Note: Check with Document
Control for current revisions of all referenced documents.

ZELTIQ Aesthetics Device Installation Form 
  

											
	 	 	 	 
	Account/Practice Name: _____________________	  		  		  	Main Contact: _________________________
	Physician Name: ___________________________	  		  		  	Telephone #: __________________________
	Address 1: _______________________________	  		  		  	Website: _____________________________
	Address 2: _______________________________	  		  		  	Email: ________________________________
	City: ____________	  	State/Province: ____________	  		  		  	Installer Name: _________________________
	Zip/Postal Code: ____________	  	Country: _________________	  		  		  	Installation Date: ________________________
	 	  		  		  		  		  	 
	Shipment
Information	  	 	  	 	  	Installation Check List
	 	 		 
	 Was the shipment/delivery made on-time?

 ̈ YES  ̈ NO

Comments:
	  	 	  		  	Record Serial numbers below:  

Upper

	 	  	 	  		  	Module: UPM  _________________________
	_________________________	  	 	  		  	 
	 	 		 
	 All items on packing list included with shipment?

 ̈ YES  ̈ NO
	  	 	  		  	Base
 Module:
BAM  _________________________

	Comments:	  		  	 	  		  	  
 Applicator:
V0 _________________________

	_________________________	  	 	  		  	 
	 Any visible damage to the shipping crate?

 ̈ YES  ̈ NO

Comments:

_________________________
	  	 	  		  	Applicaton V0 _________________________  

Applicator: V0 _________________________
  

 ̈ Support arm attached
  ̈ PIace protective pad on top of control unit.

	Any visible damage or evidence of tampering to the System?	  	 	  		  	 ̈ Inspect and make sure all cables running from the

Base Module to the Upper Module are secure.

	 ̈ YES  ̈
NO	  	 	  		  	             ̈ Unpack
and attach Applicator
	Comments:	  	 	  		  	             ̈ Attach
power cord
	_________________________	  	 	  		  	             ̈ Add
Coolant via Chiller inlet.
	  
 Quick Check Profile Test
  
 This test is to be conducted by an authorized ZELTIQ Representative only. Upon successful completion of the Installation Check List, proceed with:
  ̈ Select and run Quick Check Profile
  ̈ Test Vacuum / Massage Settings
  ̈ No errors occurs
during profile run
 Comments:
	  	 	  		  	 ̈ Power on system and insert EZ Card.

             ̈ Applicator Detect

             ̈ EZ Card Detect

             ̈ Liner Detect

 ̈ Record system configuration/version string that appears on the lower left hand corner of the
display
  
 __________________________________

 ̈ Confirm Vacuum start/stop via display and Applicator touch pad.

	_________________________	  	 	  		  	 ̈ Attach Patient Call cord and test Pager (if applicable)
	 	  	 	  	 	  	 	  	 	  	 
	 					 
	 ___________________
	  	 _____________
	  		  		  	 ___________________
	  	 _____________

	 					 
	 Customer Signature
	  	 Date
	  	 	  	 	  	 Installer Signature
	  	 Date

 EXHIBIT D 
 SERVICE RECORD 

  
 24 

ZELTIQ CONFIDENTIAL 
  

 

 
 4698 Willow Road, Pleasanton, CA 94588 USA 

T (925) 474 2500 / F (925) 474 2599 
 Toll Free (888) 935 8471 
 Distributor Service Report

  

																									
		 	 RMA #
	 	 Service Call #

	
    
 D
 I

S

T

R

I

B

U

T

O

R

    
	 	Name	 	 S

E

R

V

I

C

E
	 	Technician Name
	 	 	 	 	 
	 	 Street
	 	
STE/Dept        
	 	 	 Street
	 	
STE/Dept    

	 	 	 	 	 	 	 	 	 
	 	 City
	 	 State    
	 	
Postal/Zip Code        
	 	 	 City
	 	 	 	 State    
	 	
Postal/Zip Code        

	 	 	 	 	 	 	 	 	 	 		 	 	 	 
	 	 Phone
	 	 Country
	 	 	 Phone
	 	
Country

	 	 Email
	 	 	 	 	 Email
	 	 
	 Date/s Issue

Reported to
 Distributor:
	 	 
	
Zeltiq Product Serial #

(UPM, BAM or APP)
	 	Description	 	 Software Revision – current
 (lower left of GUI)
	 	 Software Revision – post
 upgrade (if applicable)

	  
     
	 	 	 	 	 	 
	  
     
	 	 	 	 	 	 
	  
     
	 	 	 	 	 	 
	  
     
	 	 	 	 	 	 
	  
     
	 	 	 	 	 	 
	 Issue
Report:
  

	
Analysis:
  

	 Action
Taken:
  
  

 Zeltiq Authorized Distributor Service Report – Zeltiq Part # FM10903-B 

  
  
  

 

 
 4698 Willow Road, Pleasanton, CA 94588 USA 

T (925) 474 2500 / F (925) 474 2599 
 Toll Free (888) 935 8471 
  

							
	 Service

Parts Used,
 Part#
	 	 Lot /

Serial #
	 	Description	 	QTY
	     
	 		 	 	 	 
	     
	 		 	 	 	 
	     
	 		 	 	 	 
	     
	 		 	 	 	 
	     
	 		 	 	 	 
	     
	 		 	 	 	 
	     
	 		 	 	 	 
	     
	 		 	 	 	 
	     
	 	 	 	 	 	 
	Service Technician
Signature:
	 Date Service Completed:

  

 

			
	 Comments:
	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 
	 	  	 

 Zeltiq Authorized Distributor Service Report – Zeltiq Part # FM10903-B 

 EXHIBIT E 
 ZELTIQ TRADE-NAMES 
  

			
		
	 COOL SCULPT
  
	 	 EZcard
  

		
	 COOL SCULPTING

 
	 	 ZELTIQ
  

		
	 CRYOLIPOLYSIS

 
	 	

		
	 SERIOUSLY COOL

 
	 	

  
 27 

ZELTIQ CONFIDENTIAL 
  

 EXHIBIT F 
 MONTHLY FORECAST, SALES, AND MARKETING REPORT 
 Distributor shall complete
the following form and submit it to Zeltiq in accordance with Section 2(b) of the Agreement. 
  

			
	 Date:                     
	 	 Distributor Name:
                                        

 Product Purchase Forecast. Distributor intends to purchase the following number of Products during the ninety
(90) day period following the date of this Sales and Marketing Report: 
 — Number of Control Units:
                     
 — Number of Applicators:                      

— Number of Procedure Cards:
                     
 Product
Purchase History. Distributor sold the following number of Products during the ninety (90) day period immediately preceding the date of this report (“Quarterly Sales”): 

— Number of Control Units:
                     
 — Number of Applicators:                      

— Number of Procedure Cards:
                     
 Specify the
following for each Product sold by utilizing the chart below as part of the Quarterly Sales: (i) Customer’s name and address and primary medical specialty (e.g., dermatologist, plastic surgeon), (ii) date of installation of the Zeltiq
Control Unit (as defined below), and (iii) the instrument model, serial number for all Products sold. 
  

									
	 Products
	  	 Customer Name/Address
	  	 Medical
Specialty
	  	 Date of
Installation
	  	 Serial Number

					
	 Control Unit

Applicator
 Procedure Cards
	  		  		  		  	
					
	 Control Unit

Applicator
 Procedure Cards
	  		  		  		  	
					
	 Control Unit

Applicator
 Procedure Cards
	  		  		  		  	
					
	 Control Unit

Applicator
 Procedure Cards
	  		  		  		  	

  
 28 

ZELTIQ CONFIDENTIAL 
  

 Inventory. The level of inventory of Service Units and Spare Parts (as defined below); and
(vii) any other information reasonably requested by Zeltiq. 
 Potential New Customers. List all new potential customers that
Distributor intends to contact, including company and individual names and contact information. 
 Key Customer Status. Describe the
status of all key customer accounts, including any contacts by Distributor and such Customers’ usage of Procedure Cards. 
 Marketing
Activity. Describe all sales and marketing activity undertaken by Distributor in connection with the Products, including all trade shows attended by Distributor and all media activity, and Distributor’s plan to undertake such activity
Distributor in the next ninety (90) days. 
 Competitive Activity Update. Describe any marketing or related activity of which
Distributor is aware by manufacturers, distributors, or other third party sellers of products and treatments that compete with the Products. 

  
 29 

ZELTIQ CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]